Annual Report 2018


BEACON®
Pharmaceuticals Limited
Light for life

Annual Report 2018



Caring
Global Patients


BEACON®
Pharmaceuticals Limited
Light for life





MISSION

To improve the quality of human life by providing innovative pharmaceutical products through continuous research and development ensuring stakeholders satisfaction.



VISION

To be regarded and recognized as one of the best value–driven pharmaceuticals companies in the Country.



GOALS

To be the market leader.

Serve our customers with quality products at a reasonable price.

Develop our employees with high potentials and an opportunity of career development.

Establish strong regional presence.

Provide our shareholders a steady asset growth and return on investment.

Recognize the suppliers as our business partners and competitors as the contributor to the market value.

Grow revenue and profit.



CORE VALUES

Committed to quality in all our activities.

Trustworthy relationship with customer.

Respect to other.

Work as a team.

Believe in winning.

Encourage innovative ideas

Corporate Social Responsibility



BEACON AT A GLANCE

Beacon Pharmaceuticals Limited, a leading Pharmaceutical Company in Bangladesh in respect of producing high-tech products like anticancer and cardiovascular portfolio. Beacon is a Public Limited Company listed with Dhaka and Chittagong Stock Exchange, which was incorporated on 12th September, 2001 as a private limited company with the Registrar of Joint Stock Companies and Firms, Dhaka, Bangladesh under the Companies Act 1994 and subsequently converted into a Public Limited Company with a mission to improve the quality of human life by providing innovative pharmaceutical products through continuous research and development by ensuring stakeholders satisfaction with the aim of becoming one of the most value driven Pharmaceutical Companies in the Country.

Beacon is a very popular name in the Pharmaceuticals Industries in Bangladesh due to its high quality products of Anticancer, cardiovascular, Gastrointestinal, Antibiotics, Anti-Coagulants, Protein Supplements, Muscle relaxant, Anti-histamine, Analg`esics and NSAIDS etc.

The Project is situated at Bhaluka, Mymensingh, Bangladesh on a piece of land of 30 Acres with the covered area of more than 1,50,000 sft., the cost of the project stands at more than US$. 50.00 Million.

The manufacturing complex of Beacon has been engineered by European consultants in order to be one of the finest facilities in the Country. Beacon is designed to conform world standard like US-FDA, UK-MHRA, TGA-Australia and WHO–cGMP. Commercial Production of BMRE project has been started in the year 2016.

Corporate Office

BEACON Business Centre
9/B/2, Toyenbee Circular Road
Motijheel C/A, Dhaka -1223



FIND INSIDE

Table of Contents

CORPORATE MANAGEMENT	**07-22**
1. Corporate Directory	09-10
2. Biography of Board of Directors and Board Secretary	11-14
4. Board Committees	15-16
5. Message from the Chairman	17-18
6. Statement of Managing Director	19-22
BEACON across the globe	**25-26**
Corporate Governance	**27-55**
1. Directors' Report to the Shareholders	28-34
2. Certification of CEO and CFO to the Board	35
3. Audit Committee Report	36-37
4. Nomination & Remuneration Committee Report	38
5. Corporate Governance - A guideline of Transparency and Accountability	39
6. Compliance Report (Annexure-1)	40-54
7. Certificate on Compliance of Corporate Governance	55

Directors' Responsibilities 57-58

Directors' Responsibilities for the Financial Statements 58

Financial Statements 59-102

1. Independent Auditors' Report 61-62
2. Statement of Financial Position 63
3. Statement of Comprehensive Income 64
4. Statement of Changes in Equity 65
5. Statement of Cash Flow 66
6. Notes to the Financial Statements 67-101
7. Fixed Assets Schedule 102

Additional Information 103-110

1. Notice of the 17th Annual General Meeting 103
2. Annual General Meeting 2017 104
3. BEACON in action both locally & globally 105-106
4. Proxy Card & Attendance Slip 110

CORPORATE MANAGEMENT





Corporate Directory

BOARD OF DIRECTORS

Mrs. Nurun Nahar Karim, Chairman

Mr. Md. Ebadul Karim, Managing Director

Mr. Md. Niazul Karim, Director

Mr. Prof. (Dr.) Syed Modasser Ali, Independent Director

Mr. Major M.A Hussain (Retd.), Independent Director

BOARD AUDIT COMMITTEE

Mr. Prof. (Dr.) Syed Modasser Ali, Chairman

Mr. Md. Ebadul Karim, Member

Mrs. Nurun Nahar Karim, Member

Mr. Giash Uddin Ahmed FCMA, Board Secretary

NOMINATION AND REMUNERATION COMMITTEE

Mr. Major M.A Hussain (Retd.), Chairman

Mr. Md. Ebadul Karim, Member

Mr. Md. Niazul Karim, Member

Mr. Giash Uddin Ahmed FCMA, Board Secretary

EXECUTIVE MANAGEMENT

Mr. Md. Ebadul Karim, Managing Director

Ms. Risana Karim, Executive Director

Mr. Md. Golam Robbani, Director (Plant Operations)

Mr. Giash Uddin Ahmed FCMA, EVP (Finance & Accounts)

Mr. Monjurul Alam, EVP (Business Development)

Mr. Md. Aminul Hoque, EVP (Sales)

Mr. Mr. Md. Hanif, EVP (Marketing)

Mr. Md. Shafiul Islam, SVP (MIS & Audit)

Mr. Md. Anisur Rahman Khan, SVP (HR & Admin)

MANAGEMENT STRATEGIC COMMITTEE

Mr. Md. Golam Robbani, Director (Plant Operations)

Mr. Giash Uddin Ahmed FCMA, EVP (Finance & Accounts)

Mr. Monjurul Alam, EVP (Business Development)

Mr. Md. Aminul Hoque, EVP (Sales)

Mr. Mr. Md. Hanif, EVP (Marketing)

Mr. Md. Shafiul Islam, SVP (MIS & Audit)

Mr. Md. Anisur Rahman Khan, SVP (HR & Admin)

Mr. Md. Zia Uddin Takhur, VP (HR & Admin)

Mr. Sujit Kumar Kundu, VP (PI)

MR. S. M. Mahmudul Hoque, VP (Oncology & Biotech)

Mr. Dr. Mohammad Mahbubur Rahman, VP, Sales (Onco & Bio)

Mr. Md. Saiful Islam, VP (Distribution)

Mr. Md. Shaheenur Rahman, VP (Sales)

COMPANY SECRETARY

Mr. Giash Uddin Ahmed FCMA

STATUTORY AUDITORS

M/S. Safiq Basak & Co. Chartered Accountants
House No. 42 (First Floor), Road No-1, Block–A, Niketan
Adabor, Dhaka - 1212, Bangladesh

CORPORATE GOVERNANCE COMPLIANCE AUDITOR

Poddar & Associates,
Cost and Management Accountants,
6/A/1 (Ground floor), Segun Bagicha, Dhaka-1000

LEGAL ADVISOR

Abul Khayer & Associates
25/A Indira Road, Farmgate, Dhaka

Listing

1. Dhaka Stock Exchange Ltd.
2. Chittagong Stock Exchange Ltd.

Registered Office

Beacon Pharmaceuticals Ltd.
Kathali, Bhaluka, Mymensingh, Bangladesh

Corporate Office

Beacon Business Centre

9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223

Tel: +880-2-57165371-6, Fax: +880-2-57165379-80

E-mail: beacon@beaconpharma.com.bd

Website:www.beaconpharma.com

Factory

Kathali, Bhaluka, Mymensingh

Main Banker

Janata Bank Ltd.
Agrani BankLtd.
Dutch Bangla Bank Ltd.
Bank Asia Ltd.
Shahjalal Islami Bank Ltd.
Social Islami Bank Ltd.
ICB Islamic Bank Ltd.
Sonali Bank Ltd.
Rupali Bank Ltd.
First Security Islami Bank Ltd.
BRAC Bank Limited
Eastern Bank Ltd.
Commercial Bank of Ceylon

BIOGRAPHY OF
BOARD OF DIRECTORS and COMPANY SECRETARY

BOARD OF DIRECTORS

Mrs. Nurun Nahar Karim, Chairman

Mr. Md. Ebadul Karim, Managing Director

Mr. Md. Niazul Karim, Director

Mr. Prof. Dr. Sayed Modasser Ali, Independent Director

Mr. Major M.A Hussain (Retd.), Independent Director

COMPANY SECRETARY

Mr. Giash Uddin Ahmed FCMA



Mrs. Nurun Nahar Karim
Chairman

Mrs. Nurun Nahar Karim is an MSS (Pol. Science) from Dhaka University. She is the wife of Mr. Md. Ebadul Karim. Mrs. Nurun Nahar Karim is the Chairman of BEACON Pharmaceuticals Limited, Beacon Developments Limited, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Beacon Oncology Limited, Beacon Cephalosporin Limited, Beacon Power Systems Limited and Vice-Chairman of Mujibunnessa Medical College & Hospital Limited. She is also the Director of Beacon Point Limited, Beacon Medicare Limited, Beacon Economic Zone Limited and Kohinoor Chemicals Co. (BD) Ltd, one of the largest and leading soaps, cosmetics and toiletries manufacturing company in the Country.



Mr. Md. Ebadul Karim
Managing Director

Mr. Md. Ebadul Karim, entered into the realm of business horizon after completion of his graduation. By virtue of his entrepreneurial skill and sound management capability accompanied with vast experience and farsighted vision he has been running a number of business enterprises very successfully. He is the Managing Director of Beacon Pharmaceuticals Limited, Beacon Developments Limited, Beacon Cephalosporin Limited, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Mujibunnessa Medical College & Hospital Limited, Beacon Oncology Limited, Beacon Power Systems Limited and Chairman of Beacon Point Limited, Beacon Medicare Limited, EREBA Capsules Limited and Beacon Economic Zone Limited. He is also the Director of Kohinoor Chemicals Co. (BD) Ltd., one of the largest and leading soaps, cosmetics and toiletries manufacturing company in the Country. He has travelled many countries of the world for business purposes.



Mr. Md. Niazul Karim
Director

Mr. Md. Niazul Karim, S/O. Mr. Md. Ebadul Karim is a BBA completed from the International University of Bangladesh. Just after completing his BBA he has actively involved in the business and presently he is acting as the Director of Beacon Pharmaceuticals Limited, Beacon Developments Limited, Beacon Cephalosporin Limited, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Mujibunnessa Medical College & Hospital Limited, Beacon Oncology Limited, Beacon Power Systems Limited and Managing Director of Beacon Point Limited, Beacon Medicare Limited and Beacon Economic Zone Limited.



Mr. Prof. Dr. Syed Modasser Ali
Independent Director

Prof. Dr. Syed Modasser Ali FRCS, FRCOpth is an ophthalmic surgeon from Bangladesh and was the Health and Family Welfare and Social Welfare adviser to the Govt. of the Peoples Republic of Bangladesh Prime Minister, from 2009 to 2013 He is the founder of Mojibunnessa Eye Hospital, the first registered eye hospital in Bangladesh. He is regarded as one of the pioneers of Community Ophthalmology (public eye health) and his book titled Community Ophthalmology, published in 1985, is considered by the British Journal of Ophthalmology as the first textbook on the subject. He is a recipient of Bangladesh National Personality Research Centre's Freedom Fighter Award for his contribution during the Bangladesh Liberation War. He was also an Executive Board member of the World Health Organisation. Mr. Ali was named as one of the 20 most innovative surgeons alive in 2013 by healthcare education website.

Prof. Dr. Syed Modasser Ali FRCS, FRCOpth is an ophthalmic surgeon from Bangladesh and was the Health and Family Welfare and Social Welfare adviser to the Govt. of the Peoples Republic of Bangladesh Prime Minister, from 2009 to 2013 He is the founder of Mojibunnessa Eye Hospital, the first registered eye hospital in Bangladesh. He is regarded as one of the pioneers of Community Ophthalmology (public eye health) and his book titled Community Ophthalmology, published in 1985, is considered by the British Journal of Ophthalmology as the first textbook on the subject. He is a recipient of Bangladesh National Personality Research Centre's Freedom Fighter Award for his contribution during the Bangladesh Liberation War. He was also an Executive Board member of the World Health Organisation. Mr. Ali was named as one of the 20 most innovative surgeons alive in 2013 by healthcare education website.

Prof. Ali was the Health and Family Welfare and Social Welfare adviser to the Govt. of Peoples Republic of Bangladesh, Prime Minister, from 2009 to 2013, with the full rank and status of a senior cabinet minister. He was one of seven advisers (one of only five with a portfolio) to the government providing the prime minister and the cabinet adviser on various national and international issues. He was also a member of the Executive Committee of the National Economic Council, the highest political authority for consideration of development projects in Bangladesh, during this time.

He was the Director-General of Health Services for the Bangladesh government in 2001, Dean of the Faculty of Postgraduate Medicine and Research at Dhaka University from 1998 to 2001, Chairman of the Bangladesh Medical Research Council (BMRC) from 1998 to 2003 and Director and Professor Emeritus of the National Institute of Ophthalmology in Dhaka, Bangladesh from 1997 to 2001. He was also the president of the Ophthalmic Society of Bangladesh. Under his chairmanship BMRC was awarded the prestigious WHO 50th Anniversary Primary Healthcare Development Award in 1998.



Mr. Major M. A. Hussain (Retd.)
Independent Director

Mr. M.A Hossain served in Bangladesh Army as Major in 1976. He also served as DAAG (Deputy Asst. Adjutant General) in 24 divisional HQ. He Joined in Bangladesh Bank on deputation in 1985 and got absorbed having seniority from the date of commission. Mr. Hussain retired from Bangladesh Bank as General Manager in 2008.



Mr. Giash Uddin Ahmed FCMA
Board Secretary

Mr. Giash Uddin Ahmed is a Cost and Management Accountant and done his Masters of Commerce in Accounting from the University of Dhaka. He is a fellow member of the Institute of Cost & Management Accountant of Bangladesh. He is also a certified financial consultant of the Institute of Financial Consultants, Vancouver, Canada. Prior to joining BEACON Pharma, he was the CFO (Bangladesh operation) of Otobi Ltd. He has more than 30 years of experience in different managerial capacities in the country and abroad.

BOARD AUDIT COMMITTEE
NOMINATION & REMUNERATION COMMITTEE
EXECUTIVE MANAGEMENT &
MANAGEMENT STRATEGIC COMMITTEE



Mr. Md. Ebadul Karim
Managing Director
Member, Board Audit Committee,
NRC & Executive Management



Mrs. Nurun Nahar Karim
Chairman
Member, Board Audit Committee



Mr. Md. Niazul Karim
Director
Member, Nomination &
Remuneration Committee



Mr. Prof. Dr. Syed Modasser Ali
Independent Director
Chairman, Board Audit Committee



Mr. Major M. A. Hussain (Retd.)
Independent Director
Chairman, Nomination &
Remuneration Committee



Ms. Risana Karim
Executive Director
Member, Executive Management



Mr. Md. Golam Robbani
Director, Factory Operations
Member, Executive Management &
Management Strategic Committee



Mr. Giash Uddin Ahmed FCMA
Board Secretary & EVP, F & A
Secratary, Board Audit Committee,
NRC, Executive Management &
Management Strategic Committee



Mr. Monjurul Alam
EVP, Business Development
Member, Executive Management &
Management Strategic Committee



Mr. Mohammad Hanif
EVP, Marketing
Member, Executive Management &
Management Strategic Committee



Mr. Md. Aminul Hoque
EVP, Sales
Member, Executive Management &
Management Strategic Committee



Mr. Shafiul Islam
SVP, MIS & Audit
Member, Executive Management &
Management Strategic Committee



Mr. Anisur Rahman Khan
SVP, HR & Admin
Member, Executive Management &
Management Strategic Committee



Message from the CHAIRMAN

> our loyal and dedicated employees have tried to overcome most of the adverse situations and presented a reasonable growth result with a commitment for the better in future

Dear shareholders,

It's indeed my great pleasure to welcome you all in the 17th Annual General Meeting of the Company and to place before you the Annual Report along with the Audited Financial Statements as well as Compliance Report of the Company for the year ended 30th June, 2018.

Although we have not achieved our target but I strongly believe that there was no deficiency in relentless effort of our dedicated team. However our loyal and dedicated employees have tried to overcome most of the adverse situations through their utmost effort and strong belongingness with the Company and presented a reasonable growth result with a commitment for the better in future.

Finally, on behalf of the Board and on my own behalf I like to congratulate and thanks to all of Beacon's employees for their hard working throughout 2018 and our shareholders, customers and stakeholders for their continued supporting and look forward to a successful year 2019.

Nurun Nahar Karim

Nurun Nahar Karim
Chairman



Statement of MANAGING DIRECTOR

> ...we are proud to play our part in shaping the future of corporate best practices in Bangladesh with the idea of delivering value for shareholders today while investing for tomorrow.

Dear Shareholders,

After apparels the Pharmaceuticals Industry has been one of the success stories of Bangladesh in the last three decades. Bangladesh had to depend largely for medicines on multinational companies and imports in the 1970s and early 80s. Now local companies meet almost 98 percent of domestic demand worth around USD 2 billion. The sector is not only catering to domestic needs but also exporting to over 115 countries including the United States and Europe. Pharmaceutical exports were close to USD 100 million in the fiscal year 2016-17. With the development trend of Bangladesh Pharmaceuticals market, we are in the right track and insahallah we have completed another year with global trade war between USA and China that reflects more or less negative impact all over the countries in the globe. However we have achieved the operational result of the company stated below.

Operating Result:

a. Turnover has been increased by 27.55% over last year.
b. Gross Profit has been increased by 25.25% over last year.
c. Operating Profit has been decreased by 0.87% over last year.
d. Net Profit after tax has been increased by 21.56l% over last year.
e. Net Asset value per share has been increased by 0.31% over last year.

New Products:

As a sophisticated pharmaceutical company, we focus our efforts where we can have the most impact. Our products are of different therapeutic segments like Levofed (Norepinephrine injection) for Septic shock with hypotension, Heparon (Heparin Sodium injection) as anticoagulant, Doxoven (Doxophylline tablet) for asthma & COPD, Diacer Plus (Diacerin plus Glucosamine tablet) for osteoarthritis, Fapdol (Paracetamol plus tramadol tablet) as pain killer, Paloxi capsule (Palonosetron capsule) as antiemetic, Starcef 400 (Cefixime capsule) an antibiotic, Humphry(Calcium orotate tablet) for calcium supplement, Alvenor for Piles, Tafecta (Tenofovir Alafenamide) for Hepatities, Jaktor for Rheumatoid Arthrities, Soforal (Sofosbuvir tablet) and Daclavir (Daclatasvir tablet) for Hepatitis-C, Cetuxim (Cetuximab inj) for

Head & Neck cancer, Bivastim 400 (Bivasizumab) for Colorectal cancer, Dasanix (Dasatinib) for Blood cancer, Pemetrex (Pemetrexed) for Lung cancer, Cytabin (Cytarabin) and Velvin for Blood cancer etc.

Our Global Business:

Global patient support program was introduced in 2016 under which we have been serving to the patients of more than 114 countries of the world including the developed countries of Europe, America, Australia, Africa & Asia through our latest lifesaving drugs. Lifesaving drugs are still beyond the reach of patients even in advanced countries. Considering this, we have introduced our products at a very affordable price and much lower than the originator products. In this connection, we would like to inform that the quality of our products is checked by International Standard Laboratories in USA, Australia and China, where they have got satisfactory results.

This novel effort of Beacon continued to maintain its appreciation in international media and made bench mark by being featured in BBC and global news media. Beacon is in the Head line of different country's news media including Economic Times of India, The Mirror, UK, Sri Lankan Times etc.

Besides our Global Patient support program, Beacon proved their presence as No-1 Oncology Company in Nepal and did extremely well in Sri Lanka, Philippines and Myanmar. Beacon has sponsored various international conference including ESMO 2018-Madrid, Spain; ELCC-Geneva, Switzerland; 6th Asian conference on Hepatitis & AIDS, 5th World congress on Hepatitis & Liver Diseases-London, UK; South East Asian Breast Cancer Symposium-Myanmar; ESMO Asia 2017-Singapore; CAB- Georgia and SFO- Sri Lanka. In addition, it conducted CMEs in countries Kosovo, Myanmar, Nepal and Sri Lanka. The team has established Beacon as a reliable, trusted, quality driven oncology company. We are registering our products in Latin America, Cambodia, Moldova and hope to start business in 2019.

Dear shareholders, I have established this company with a hope to become with global vision. Our Global Team continuing adding new business spectrum in this journey. I



hope that our Global Business Team will make us globally more popular and Beacon will be the trusted name to meet the scarcity of life saving drugs globally.

Our Commitment:

BEACON passionately believes that success and responsibility go together. We are committed to the social and economic development of Bangladesh, As one of the leading drugs manufacturing Company in the Country, we are proud to play our part in shaping the future of corporate best practices in Bangladesh with the idea of delivering value for shareholders today while investing for tomorrow.

Conclusion:

Finally, I express my sincere thanks to all the stakeholders of the Company for their confidence on us and valuable contribution to the company throughout 2018. The guidance from our Board of Directors has always been instrumental in shaping the success of the Company. We are grateful to millions of our consumers who have been with us, along with their smart choice and dedication towards us and our brands. We believe passionately in building value for our consumers and shareholders.
I also look forward to having continuous support from you all.

Thank you all,



Md. Ebadul Karim
Managing Director

Humphry

Calcium Orotate INN 400 mg tablet

Maximum Utilized Calcium for Bone

MAX
theory ensures maximum utilization of Calcium

- **Maximum Absorption**
- **Maximum Transportation**
- **Maximum Delivery**



Each sachet of Humphry tablet ensures double protection from moisture & high temperature

BEACON® Pharmaceuticals Limited
Light for life

Multiple Unit Pellet System

Esoprex MUPS

Esomeprazole

....can be taken before or after meal

Tablet	20 mg
	40 mg

Uniform drug **absorption**
& greater **bioavailability** ensures better efficacy



MUPS Tablet
Once daily
Dosing

BEACON®
Pharmaceuticals Limited
Light for life

BEACON across the globe



BEACON'S stall in European Society of Medical Oncology (ESMO) Congress 2018 in Germany



Global oncologists in gala dinner of BEACON in Germany



The Sri Lankan Doctors in our meeting who are making BEACON no 1 in oncology



Meeting with Kenyan oncologists in Conference on Liver Disease in Africa (COLDA) 2018, Keyna



Breast cancer awareness campaign 2018 in Nepal organized by BEACON



European oncologists in meeting with BEACON officials

BEACON across the globe



European oncologists in meeting with BEACON officials



Uzbekistan oncologists & regulatory authority in BEACON's stall



China International Medical Tourism Fair 2018, Shanghai



BEACON's stall in Highlights of ASH in Asia-Pacific 2018, Bali, Indonesia



Indonesian oncologists in meeting with BEACON officials



Nepal oncologists in BEACON's stall during NCHCON 2018

CORPORATE GOVERNANCE

Directors' Report to the Shareholders For the year ended 30th June, 2018



CORPORATE GOVERNANCE

Directors' Report to the Shareholders For the year ended 30th June, 2018

Dear Shareholders

The Directors have the pleasure to present their Annual Report together with the Audited Financial Statements of the Company for the year ended 30th June, 2018. These were approved by the Board of Directors on 21st October, 2018. The Directors' Report has been prepared in compliance with section 184 of the Companies Act. 1994, SEC's notification dated 20th February 2006, the Listing Regulations of Dhaka and Chittagong Stock Exchange and other applicable rules and regulations. In addition, the Directors explained and disclosed certain issues, which they deemed relevant and important to ensure transparency and good governance practice.

i. Industry outlook and possible future development in the industry.

The principal activities of the Company are to manufacturing, marketing and selling of pharmaceuticals and lifesaving medicine in the local and international markets. Beacon is the first manufacturer of anti-cancer drugs in Bangladesh and proud introducer of isolator technology for processing anti-cancer products and lyophilized technology. Beacon is the second in world to manufacturing and marketing peginterferon medicine for hepatitis. Beacon is the first to introduce sophisticated biotech products streptokinase and Urokinase injections for Acute MI disease. This year Beacon has launched 13 nos. of new products, out of which 6 general products, 4 oncology products and 3 bio-tech products.

Despite of some unfavorable events we were able to maintain revenue at a reasonable level. Moreover, we have given special emphasis on cost control, resource optimization and R & D capabilities in order to face these economic challenges.

ii. Segment-wise or product-wise performance.

Our products can be segmented as General, Oncology and Bio-tech products. In terms of volume of sale General Product is the best performer followed by Oncology and Bio-tech respectively. In the sales performance, general products have contributed more than 60%, 32% oncology and rest 8% contributed by Bio-tech Products. In respect of profit margin Oncology Products are the best contributor than that of others.

iii. Risk and Concerns.

Risks are defined as uncertainties resulting in adverse variations of profitability or losses in financial or otherwise. The risk management of the company covers core risk areas of the business operation viz, financial risk, operational risk, receivable risk, liquidity risk, market risk that includes foreign exchange risk, interest rate risk etc. Besides above risks, the Company considers credit management risks and strategic risks also.

The Company has a strong base to address the risk of future uncertainties with the change of industry and global economy. The company is always keen to identify the key business risks and ensures the mitigation plans are in place. It has reviewed and adopted best practices of the industry that are articulated to enable the company to achieve its objectives effectively.

The objective of risk management is that the Company evaluates and takes well calculative business risks that safeguarding the asset, its financial resources and profitability from various businesses through its own measures and through implementing corporate guidelines.

iv. Discussion on Cost of Goods Sold, Gross Profit Margin and Net Profit Margin.

Cost of Goods Sold for the year stands at Tk. 1,927,331,673 which is 29.82% higher than that of the previous year. This has been occurred due to increase of sales by 27.55% compare to the previous year and Gross Margin has been increased by 25.25% over the last year. Due to strong control over the operating expense net margin has been increased by 21.56% over the last year.

v. Discussion on continuity of any Extra-Ordinary gain or loss.

No extra ordinary gain or loss occurred during the year which would require adjustment or disclosure in the financial statements.

vi. Basis for related party transactions.

Related Party Transactions are disclosed in the notes 43 to the Financial Statements for the year ended 30th June, 2018.

CORPORATE GOVERNANCE

Directors' Report to the Shareholders For the year ended 30th June, 2018

vii. Utilization of proceeds from public issues, rights issues and / or through any other instruments.
During the financial year 2017-2018 no such proceeds are collected that would require for adjustment or disclose in the annual report.

viii. Explanation if the financial results deteriorate after the Company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Right Offer and Direct Listing.
Beacon Pharmaceuticals Limited went for initial public offering in the year 2010 and did not go for any further offering since then. So, no such explanation is required for Beacon Pharmaceuticals Limited.

ix. Explanation the significance variance occurs between Quarterly Financial Performance and Annual Financial Statements.
There was no significant variance occurred between the quarterly financial performance and annual financial statements.

x. Remuneration to directors including independent directors.
Remuneration and other perquisites of the Directors are reviewed annually and approved by the Chairman of the Board. Non-Executive Directors including the Independent Directors are paid fees for attending the meetings only.

xi. Financial Statements prepared by the management of the Company presents fairly its state of affairs, the result of its operation, cash flows and changes in equity.
The financial statements together with the notes thereon have been drawn up inconformity with the Companies Act 1994 and the Securities and Exchange Rules 1987. These statements present fairly the Company's state of affairs, the result of operation, cash flow and changes in equity.

xii. Proper books of accounts of the Company have been maintained.
Books of Accounts of the Company have been maintained properly.

xiii. Accounting Policies:
Appropriate accounting policies have been consistently applied in preparing financial statements and the accounting estimates are based on reasonable and prudent judgment.

xiv. Application of IAS/BAS/IFRS/BFRS as applicable in Bangladesh.
International Accounting Standard (IAS) / Bangladesh Accounting Standard (BAS) / International Financial Reporting Standard (IFRS) / Bangladesh Financial reporting Standards (BFRS) as applicable in Bangladesh have been followed in preparing financial statements and any departure there from has been adequately disclosed.

xv. The system of internal control.
The system of internal control is sound and has been implemented and monitored effectively. The Board has the ultimate responsibility for Beacon Pharma's system of internal control and for reviewing its effectiveness. It has been designed to manage the risk of failure to achieve the objectives of the Company and to provide reasonable assurance that Company's assets are safe guarded against unauthorized use of material loss and that transactions are properly authorized and recorded.

xvi. Going Concern.
There are no significant doubts about the Company's ability to continue as a going concern. The Board of Directors has reviewed the Company's business plan and is satisfied that the Company has adequate resources to continue its operations in the foreseeable future. Accordingly the financial statements are prepared based on the going concern concept basis.

xvii. Explanation of significant deviation from the last year's operating result.
Significant variations over the last year's operation of the Company have been made due to excess expenditure incurred in the factory overhead, general & admin overhead and selling and distribution overhead. The positive impact of excess expenditures are gradually coming. Hopefully the growth of turnover will dramatically change in the years to come.

CORPORATE GOVERNANCE

Directors' Report to the Shareholders For the year ended 30th June, 2018


5 (Five) Years Financial Highlights:

Particulars			Year		
Financial Performance	**2018**	**2017**	**2016**	**2015**	**2014**
Total Assets	4,908,410,740	5,105,979,654	5,014,603,610	4,738,697,597	4,589,825,300
Total Liabilities	1,907,666,832	2,114,679,364	2,012,513,836	1,832,571,953	1,722,443,291
Current Assets	2,400,038,430	2,424,721,610	2,563,219,957	2,551,804,834	2,157,357,740
Current Liabilities	1,332,666,250	1,138,029,634	1,150,667,724	1,127,282,634	1,062,083,274
Non-Current Assets	2,508,372,310	2,681,258,044	2,451,383,653	2,186,892,763	2,432,467,559
Non-Current Liabilities	575,000,582	976,649,730	861,846,112	705,289,319	660,360,017
Shareholders' Equity	3,000,743,908	2,991,306,829	3,002,089,774	2,906,125,644	2,867,382,009
Operational Performance					
Revenue	3,760,786,106	2,948,456,509	2,491,804,435	2,052,938,834	1,690,363,446
Cost of Goods Sold	1,927,331,673	1,484,623,696	1,292,608,372	1,061,613,363	894,119,555
Operating Expense	1,563,846,092	1,196,557,774	935,102,873	706,291,686	553,676,280
Financial Expense	138,160,282	147,375,018	194,721,492	238,236,937	221,684,367
Gross Profit	1,833,454,433	1,463,832,813	1,199,196,063	991,325,471	796,243,891
Operating Profit	269,608,341	267,275,039	264,093,190	285,033,785	242,567,610
Net Profit before tax	126,035,753	115,895,985	68,308,534	51,407,588	37,274,146
Net Profit after tax	126,103,008	103,734,641	61,402,978	38,555,691	24,228,195
Financial Ratio					
Current ratio	1.80:1	2.13:1	2.23:1	2.26:1	2.03:1
Debt Equity Ratio	1:1.57	1:1.41	1:1.49	1:1.58	1:1.66
Financial Expense Coverage Ratio (Times)	1.95	1.81	1.36	1.20	1.09
Return on Equity	4.20%	3.47%	2.04%	1.33%	0.85%
Return on Assets	2.57%	2.03%	1.22%	0.81%	0.53%
Equity Parameters					
Authorized Capital	3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000
Paid-up Capital	2,310,000,000	2,310,000,000	2,310,000,000	2,310,000,000	2,310,000,000
Shareholders' Equity	3,000,743,908	2,991,306,829	3,002,089,774	2,906,125,644	2,867,382,009
No. of Shares Outstanding	231,000,000	231,000,000	231,000,000	231,000,000	231,000,000
Net Assets Value (NAV) Per Share	12.99	13.37	13.00	12.58	12.41
Earnings Per Share (EPS)	0.55	0.45	0.27	0.17	0.10
Market Price Per Share (Closing)	17.80	23.10	17.30	14.70	14.80
Price Earnings Ratio (Times)	32.36	51.33	64.07	86.47	148.00

CORPORATE GOVERNANCE


Directors' Report to the Shareholders
For the year ended 30th June, 2018

Sales (million)




Net Revenue

Gross Profit (million)




Gross Profit

Net Profit (million)




Net Profit

EPS (BDT)




Earning Per Share

Shareholders Equity (million)



Shareholders Equity

ROE ROA



Return On Equity & Assets

Directors' Report to the Shareholders
For the year ended 30th June, 2018

xix. Declaration of dividend.

The Board of Directors of the Company has recommended 6% cash dividend for the year ended 30th June, 2018.

xx. Number of board meeting held during the year and attendance of each director.

During the year 16 nos. of Board Meetings were held. The attendance record of the Directors is shown below. The Directors who could not attend the meeting were granted leave of absence.

Board Meeting and attendance during the year ended 30th June, 2018

Sl. No.	Name of Directors	Meeting held	No. of meeting attended
1.	Mrs. Nurun Nahar Karim, Chairman	16	16
2.	Mr. Md. Ebadul Karim, Managing Director	16	16
3.	Mr. Md. Niazul Karim, Director	16	15
4.	Mr. Prof.(Dr.) Syed Mudasser Ali, Independent Director	16	11
5.	Mr. Major M. A. Hussain (Retd.), Independent Director	16	04

Pattern of Shareholding

a) Parent/Subsidiary/ Associated Companies and other related parties.

Sl. No.	Name	Designation with BPL	Entities where they have interest	No. of share held
1.	Mr. Md. Ebadul Karim	Managing Director	Beacon Developments Ltd.	600
			Beacon Cephalosporin Ltd.	25,50,000
			MEK Auto Bricks	25,000
			MEK Industries Ltd.	8,500
			MEK Pharmatech Ltd.	8,500
			Mujibunnessa Medical College & Hospital Ltd.	80,00,000
			Beacon Oncology Ltd.	85,000
			Beacon Power Systems Ltd.	85,000
			Beacon Nutraceuticals Ltd.	85,000
		Chairman	Beacon Point Ltd.	25,000
			Beacon Medicare Ltd.	42,500
			EREBA Capsules Ltd.	20,000
			Beacon Economic Zone Ltd.	8,00,000
		Director	Kohinoor Chemical Co.(BD) Ltd.	10,96,992

CORPORATE GOVERNANCE

Directors' Report to the Shareholders
For the year ended 30th June, 2018

Sl. No.	Name	Designation with BPL	Entities where they have interest	No. of share held
2.	Mrs. Nurun Nahar Karim	Chairman	Beacon Developments Ltd.	250
			Beacon Nutraceuticals Ltd.	5,000
			MEK Auto Bricks	12,500
			MEK Industries Ltd.	500
			MEK Pharmatech Ltd.	500
			Beacon Oncology Ltd.	5,000
			Beacon Cephalosporin Ltd.	1,50,000
			Beacon Power Systems Ltd.	5,000
		Vice-Chairman	Mujibunnessa Medical College & Hospital Ltd.	5,00,000
		Director	Beacon Point Ltd.	25,000
			Beacon Medicare Ltd.	2,500
			Beacon Economic Zone Ltd.	50,000
			Kohinoor Chemical Co. (BD) Ltd.	7,01,353

Sl. No.	Name	Designation with BPL	Entities where they have interest	No. of share held
3.	Mr. Md. Niazul Karim	Managing Director	Beacon Point Ltd	25,000
			Beacon Economic Zone Ltd.	1,50,000
			Beacon Medicare Ltd.	2,500
		Director	Beacon Developments Ltd.	400
			Beacon Cephalosporin Ltd.	1,50,000
			Beacon Nutraceuticals Ltd.	5,000
			MEK Auto Bricks	6,250
			MEK Industries Ltd.	500
			MEK Pharmatech Ltd.	500
			Beacon Oncology Ltd.	5,000
			Mujibunnessa Medical College & Hospital Ltd.	5,00,000
			Beacon Power Systems Ltd.	5,000

b) Director, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and their spouse and minor children.

SL. No.	Name	Designation	No. of Shares Held
1	Mr. Md. Ebadul Karim	Managing Director	5,82,28,800
2	Mrs. Nurun Nahar Karim	Director	47,25,000
3	Mr. Md. Niazul Karim	Director & CFO	63,54,000
4	Mr.Giash Uddin Ahmed	Company Secretary	200,000
5	Mr. Muhammad Mahbubul Alam	Head of Internal Audit	Nil
6	Spouse & Minor Children		Nil

(c) Executive

SL. No.	Name	Designation	No. of Shares Held
1	Mr. Md. Ebadul Karim	Managing Director	5,82,28,800
2	Mr. Md. Niazul Karim	Director & CFO	63,54,000

(d). Shareholders holding ten percent (10%) or more voting interest in the Company.

SL. No.	Name	Designation	No. of Shares Held
1	Mr. Md. Ebadul Karim	Managing Director	5,82,28,800

xxi. Recommendation for re-appointment of Directors:

As per provision of the Articles of Association of the Company Mr. Md. Niazul Karim will retire by rotation in the next 17th Annual General Meeting and being eligible he will be offered for re-appointment.

xxii. Appointment of Auditors:

Pursuant to section 210 of the Companies Act 1994, Company's statutory Messrs Shafiq Basak & Co., Chartered Accountants will retire at the 17th Annual General Meeting as auditor of the Company.

The retiring auditors are eligible for re-appointment and they have expressed their willingness to be appointed as auditor of the Company for the financial year 2018-2019. The Directors recommended for the re-appointment of Messrs Shafiq Basak & Co, Chartered Accountants as the auditors of the Company for the year 2018-2019.

xxiii. Corporate Governance Compliance Report:

In accordance with the requirement of Bangladesh Securities and Exchange Commission "Corporate Governance Compliance Report" is shown in the annexure - I of this report.

xxiv. Conclusion:

The Company expresses its sincere appreciation to all of its employees for their outstanding contribution and thanks to all the stakeholders for their continued support and confidence.

Approved by the Board of Directors and signed on its behalf.

Md. Ebadul Karim
Managing Director

CORPORATE GOVERNANCE

Beacon Pharmaceuticals Limited
Declaration by CEO and CFO

Date: 1st October, 2018

The Board of Directors
Beacon Pharmaceuticals Limited.
Beacon Business Center.
9/B/2, Toyenbee Circular Road, Motijheel.
Dhaka-1223

Subject: Declaration on Financial Statements for the year ended on 30th June, 2018.


Dear Sirs,
Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, Dated 3rd June, 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

1) The Financial Statements of Beacon Pharmaceuticals Limited for the year ended on 30th June, 2018 have been prepared in compliance with International Accounting Standards (IAS) on International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there form has been adequately disclosed;
2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriated and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that:-

i) We have reviewed the financial statements for the year ended on 30th June, 2018 and that to the best of our knowledge and belief.
   a) these statements do not contain any materiality untrue statement or omit any material fact or contain statements that might be misleading;
   b) these statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely Yours,



Md. Ebadul Karim
Managing Director



Md. Niazul Karim
Director (Finance)

CORPORATE GOVERNANCE

Audit Committee Report

Composition of Audit Committee:

The Board of Directors of Beacon Pharmaceuticals Limited has formed an Audit Committee comprising the following three Directors as per Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, dated 3rd June, 2018 of Corporate Governance Code of Bangladesh Securities and Exchange Commission.

1.	Mr. Prof. (Dr.) Syed Modasser Ali, Independent Director	Chairman of the Committee
2.	Mr. Md. Ebadul Karim, Managing Director	Member
3.	Mrs. Nurun Nahar Karim, Chairman	Member
4.	Mr. Giash Uddin Ahmed FCMA, Company Secretary	Secretary

Role and Responsibility of the Audit Committee:

The Audit Committee is empowered to consider any matter relating to the financial affairs of the Company and to review all internal and external audit, internal control system, procedures and accounting policies etc of the Company so as to ensure that a sound financial reporting system is in place in order to provide an accurate, appropriate and timely information to the management, regulatory authorities and to the shareholders.

Meetings held of the Audit Committee:

4 (Four) number of meetings were held of the audit committee during the year where a detailed discussion was made relating to quarterly and final accounts of the Company.

Activities of Audit Committee:

The following activities were carried out by the audit committee during the financial year as per terms of reference of the audit committee.

Financial Reporting:

Review quarterly, half yearly and final accounts of the Company prior to submission to the Board of Directors for approval. The review was to ensure that financial reporting and disclosures were in compliance with the Securities Laws, provision of Company's Act 1994, applicable Accounting Standards / IFRS, any conflict of interest and other relevant legal and regulatory requirements.

Internal Audit:

Review annual internal audit plans including the audit methodology, scope and coverage of audit activities of the Company.

Review the effectiveness of audit process, resource requirements and assess the performance of internal audit department. The competency and performance of the Head of Internal Audit is also reviewed.

Review the internal audit report which encompassed the audit issues, audit recommendations and management's response to these recommendations, actions taken in the area of internal control system and efficiency enhancement suggested by the internal auditors.

External Audit:

The Committee reviews the final accounts, auditors' findings and management response. The Committee also reviews the external auditors report and areas of concern they have highlighted in the management letter and management's response to the findings of the external auditors.

CORPORATE GOVERNANCE

Audit Committee Report

Internal Control System:

The Committee also reviews the effectiveness of internal control system of the Company and put their valuable suggestions to develop the system in order to safeguard the Company's assets and outstanding financial performance.

Recommendation:

The Audit Committee recommended to the Board of Directors that Messrs Shafiq Basak & Co., Chartered Accountants will be appointed as external auditors and Messrs Podder & Associates, Cost and Management Accountants will be appointed as compliance auditors of the Company for the financial year 2018-2019 subject to the approval of the members of the Company at the 17th Annual General Meeting.

On behalf of the Audit Committee.



Prof. Dr. Syed Modasser Ali
Independent Director
Chairman, Audit Committee
30th September, 2018

CORPORATE GOVERNANCE

Nomination and Remuneration Committee Report

Composition of Nomination and Remuneration Committee:

The Board of Directors of Beacon Pharmaceuticals Limited has formed a Nomination and Remuneration Committee comprising the following three Directors as per Notification No. BSEC/CMRRC-D/2006-158/207/Admin/80, dated 3rd June, 2018 of Corporate Governance Code of Bangladesh Securities and Exchange Commission.

1.	Mr. Major M.A Hussain (Retd.), Independent Director	Chairman of the Committee
2.	Mr. Md. Ebadul Karim, Managing Director	Member
3.	Mr. Md. Niazul Karim, Director	Member
4.	Mr. Giash Uddin Ahmed FCMA, Company Secretary	Secretary

Role and Responsibility of the Nomination and Remuneration Committee:

NRC shall be independent and responsible or accountable to the Board and to the shareholders. NRC shall oversee, among others, the following matters and make report with recommendation to the Board:

I. Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive;

II. Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;

III. Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;

IV. Formulating the criteria for evaluation of performance of independent directors and the Board;

V. Identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria; and

VI. Developing, recommending and reviewing annually the company's human resources and training policies;

On behalf of the Nomination and Remuneration Committee

Mr. Major M.A Hussain (Retd.)
Independent Director
Chairman, NRC
1st October, 2018

CORPORATE GOVERNANCE

A Guideline of Transparency and Accountability

Corporate Governance

Adopting the best practice of Corporate Governance and following the principles of transparency and accountability that protect the interest of its stakeholders and safeguarding the assets of the shareholders. Corporate Governance ensures the activities that lead the Company to its goal through setting strategies, formulating policies and taking prudent decisions. The Board of Directors of Beacon ensures that the activities undertaken by the Company are in accordance with the highest ethical standards in the best interest of all stakeholders.

The Board

The Board comprises of five members of executive and non-executive having diverse and professional skill and experience. The non-executive Directors are from different business and background. Their experience enable them to contribute the Company in making strategy, formulating policy and other decision making process for advancement. The Chairman is the head of the Board and Company Secretary is the compliance officer who prepares agenda in consultation with the Chairman of the Board of Directors and Chairman of various Committee and Managing Director. The Chairman ensures that all Board members are properly briefed on all issues raise in the Board Meeting. It is the responsibility of the Chairman and the Company Secretary to ensure that the non-executive Directors are provided with timely information to enable them to carry on the duties effectively.

Board Meetings

The Board of Directors has the supreme authority delegated by the shareholders in making strategy, formulating policy and other decision making process for development of the Company. The Board of Directors considers that it meets regularly to discharge their duties effectively.

Board Independence

As per Corporate Governance Guidelines, Mr. Prof. Dr. Syed Mudasser Ali and Mr. Major M. A. Hussain (Retd.) have been re-appointed as Independent Director of the Company. They are considered by the Board to be independent of the Company and the management and free of any business or other relationship that could interfere with the exercise of their independent judgment. The Board beliefs that, their experience and knowledge enable them to provide effective and constructive contribution to the Board.

Board Committee

The Board of Directors has formed a number of committees to assist in exercising its authority including monitoring of performance.

Board Audit Committee

The Company's Audit Committee met fourth times in 2018 to consider its Annual Financial Statements for the year ended 30th June, 2018 and the Quarterly Reports in the same financial year. The committee comprises Mr. Prof. Dr. Syed Modasser Ali, Mr. Md. Ebadul Karim and Mrs. Nurun Nahar Karim.

Nomination and Remuneration Committee

The Nomination and Remuneration Committee comprises Mr. Major M.A Hussain (Retd.), Mr. Md. Ebadul Karim and Mr. Md. Niazul Karim.

Internal Control

The Board has ultimate responsibility of Beacon Pharma's system of internal control and reviewing its effectiveness. It has been designed to manage the risk of failure to achieve the objectives of the Company and to provide reasonable assurance that Company's assets are safe guarded against unauthorized use of material losses and that transactions are properly authorized and recorded.

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Status of compliance with the conditions imposed by the Commission's Notification No.BSEC/CMRRC-D/2006-158/207/Admin/80, dated 03 June, 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9.00)

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1	**Board of Directors.-**			
1(1)	**Size of the Board of Directors**	✓		
	The total number of members of a company's Board of Directors (hereinafter referred to as "Board") shall not to be less than 5 (five) and more than 20 (twenty).	✓		The boards of Directors are comprised of 5 Directors including 02 Independent Director
1(2)	**Independent Directors**	✓		
1(2)(a)	At least one fifth (1/5) of the total number of directors in the company's board shall be independent directors;any fraction shall be considered to the next integer or whole number for calculating number of independent director(s);	✓		
1(2)(b)(i)	Who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	✓		
1(2)(b)(ii)	Who is not a sponsor of the company and is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its asscoiates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members also shall not hold above mentioned shares in the company:	✓		
1(2)(b)(iii)	Who has not been an executive of the company in immediately preceding 2(two) financial years;	✓		
1(2)(b)(iv)	Who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	✓		
1(2)(b)(v)	Who is not a member or TREC (Trading Right Entitlement Certificate) holder,director, or officer of any stock exchange;	✓		
1(2)(b)(vi)	Who is not a shareholder, director excepting independent direct or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(2)(b)(vii)	Who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	✓		
1(2)(b)(viii)	Who is not an independent director in more than 5 (five) listed companies;	✓		
1(2)(b)(ix)	Who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFI);	✓		
1(2)(b)(x)	Who has not been convicted for a criminal offence involving moral turpitude.	✓		
1(2)(c)	The independent director(s) shall be appointed by the board of directors and approved by the shareholders in the Annual General Meeting (AGM).	✓		
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90(ninety) days.	✓		
1(2)(e)	The tenure of office of an independent director shall be for a period of 3(three) years, which may be extended for 1(one) term only.	✓		
1(3)	Qualification of Independent Director (ID)			
1(3)(a)	Independent director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial, regulatory and corporate laws and can make meaningful contribution to business.	✓		
1(3)(b)(i)	Business Leader who is or was a promoter or director of an unlisted company having minimum paid -up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or bussiness association;	✓		
1(3)(b)(ii)	Corporate Leader who is or was a top level executive not lower than Chief Executive officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(3)(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least eductional background of bachelor degree in economics or commerce or bussiness or law;	✓		
1(3)(b)(iv)	University Teacher who has eductional background in Economics or Commerce or Business Studies or Law;	✓		
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	✓		
1(3)(c)	The independent director(s) shall have at least 10(ten) years of experiences in any field mentioned in clause (b);	✓		
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission.	✓		
1(4)	**Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer.-**			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director (MD) and /or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	✓		
1(4)(b)	The Managing Director (MD) and/or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	✓		
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	✓		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/ or Chief Executive officer;	✓		
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	✓		
1(5)	**The Directors' Report to the Shareholders**			
1(5)(i)	An industry outlook and possible future developments in the industry;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(5)(ii)	The Segment-wise or product-wise performance;	✓		
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	✓		
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	✓		
1(5)(v)	A discussion on continuity of any extraordinary activities and their impliacations(gain or loss);	✓		
1(5)(vi)	A detiled discussion on related party transactions along with a statement showing amount, nature of related party,nature of transactions and basis of transactions of all related party transactions;	✓		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or through any others instruments;			N/A
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO). Rights Share Offer, Direct Listing, etc;			N/A
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial Performance and Annual Financial Statements;	✓		
1(5)(x)	A statement of remuneration paid to the directors including independent directors;	✓		
1(5)(xi)	A statement that the financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	✓		
1(5)(xii)	A statement that proper books of account of the issuer company have been maintained;	✓		
1(5)(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	✓		
1(5)(xiv)	A statement that International Accounting Standards (IAS)or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followedin preparation of the financial statements and any departure there from has been adequately disclosed;	✓		
1(5)(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(5)(xvi)	A statement that minority shareholders have been protacted from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	✓		
1(5)(xvii)	A statement that there is no Significant doubt upon the issuer company's ability to continue as going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	✓		
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the resons thereof shall be explained;	✓		
1(5)(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	✓		
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend(cash or stock) for the year;			The company has declared 6% cash dividend.
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;			N/A
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	✓		
1(5)(xxiii)	A report on the pattern of shareholding disclosing the aggregate number of shares(along with name-wise details where stated below) held by:-	✓		
1(5)(xxiii)(a)	Parent or Subsidiary or Associated Companies and other related parties (name -wise details);	✓		
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance their spouses and minor children (name- wise details);	✓		
1(5)(xxiii)(c)	Executives;	✓		
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details).	✓		
1(5)(xxiv)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders:-	✓		
1(5)(xxiv)(a)	a brief resume of the director	✓		
1(5)(xxiv)(b)	nature of his/her expertise in specific functional areas;	✓		
1(5)(xxiv)(c)	Names of companies in which the person also holds the directorship and the membership of committees of the board.	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(5)(xxv)	A management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief disscission of changes in financial statements, among others, focusing on:			
1(5)(xxv)(a)	Accounting policies and estimation for preparation of financial statements;	✓		
1(5)(xxv)(b)	Changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;			N/A
1(5)(xxv)(c)	Comparative analysis (including effects of inflation) of fianacial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	✓		
1(5)(xxv)(d)	compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	✓		
1(5)(xxv)(e)	briefly explain the financial and economic scenario of the country and the globe;	✓		
1(5)(xxv)(f)	risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; and	✓		
1(5)(xxv)(g)	future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	✓		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A; and	✓		
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C.	✓		
1(6)	**Meetings of the Board of Directors**	✓		
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(7)	Code of Conduct for the Chairperson, other Board members and Chief Executive Officer			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC), for the Chairperson of the Board, other board members and Chief Executive Officer of the company;			Being formulated by NRC
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company			Will be complied after finalization of the code of conduct
2	**Governance of Board of Directors of Subsidiary Company:-**			BPL doesn't have any subsidiary
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;			N/A
2(b)	At least 1 (one) independent director of the Board of the holding company shall be a director on the Board of the subsidiary company;			N/A
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company.			N/A
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;			N/A
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.			N/A
3.	**Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO) Head of Internal Audit and Compliance (HIAC) and Company Secretary(CS):-**			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	✓		
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC) shall be filled by different individuais;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time;	✓		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	✓		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	✓		
3(2)	**Requirement to attend Board of Director's Meetings**			
	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board:	✓		
3(3)	**Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer(CFO)**			
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:			
3(3)(a)(i)	These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;	✓		
3(3)(a)(ii)	These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	✓		
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent illegal or violation of the code of conduct for the company's Board or its member;	✓		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	✓		
4.	**Board of Director's Committee.- For ensuring good governance in the company, the Board shall have at least following sub-committees:**			
4(i)	Audit Committee;	✓		
4(ii)	Nomination and Remuneration Committee	✓		
5.	**Audit Committee.-**			
5(1)	**Responsibility to the Board of Directors**			
5(1)(a)	The company shall have an Audit Committee as a sub-committee of the Board;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
5(1)(b)	The Audit Committee shall assist the Board of Directors in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	✓		
5(1)(c)	The Audit Committee shall be responsible to the Board;the duties of the Audit Committee shall be clearly set forth in writing.	✓		
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	✓		
5(2)(b)	The Board shall appoint members of the audit committee who shall benon-executive directors of the company excepting Chairperson of the Board and shall include at least 1(one) independent director;	✓		
5(2)(c)	All members of the audit committee should be "financially literate" and at least I (one) member shall have accounting or related financial management background and 10(ten)years of such experience;	✓		
5(2)(d)	When the term of service of any Committee members expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	✓		
5(2)(e)	The company secretary shall act as the secretary of the Committee.	✓		
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	✓		
5(3)(a)	The Board of Directors shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an Independent director;	✓		
5(3)(b)	In the absence of the Chairperson of the audit committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constittuting a quorum as required under condition No.5(4)(b) and the reson of absence of the regular chairperson shall be duly recorded in the minutes.	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
5(3)(c)	Chairperson of the Audit Committee shall remin present in the Annual General Meeting(AGM):	✓		
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year: Provided that any emergency meeting in addition to regular meeting may be convened at the request of any one of the members of the Committee;	✓		
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	✓		
5(5)	The Audit Committee shall:-			
5(5)(a)	Oversee the financial reporting process;	✓		
5(5)(b)	Monitor choice of accounting policies and principles;	✓		
5(5)(c)	Monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance plan and review of the Internal Audit and Compliance Report;	✓		
5(5)(d)	Oversee hiring and performance of external auditors.	✓		
5(5)(e)	Hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	✓		
5(5)(f)	Review along with the management, the annual financial statements before submission to the board for approval;	✓		
5.5(g)	Review along with the management, the quarterly and half yearly financial statements before submission to the board for approval;	✓		
5.5(h)	Review the adequacy of internal audit function;	✓		
5(5)(i)	Review the Management's Discussion and Analysis before disclosing in the Annual Report;	✓		
5(5)(j)	Review statement of all related party transactions submitted by the management;	✓		
5(5)(k)	Review Management Letters or Letter of Internal Control weakness issued by statutory auditors.	✓		
5(5)(l)	Oversee the determination of audit fees based on scope and magnitude, level of experise deployed and time required for effective audit and evalute the performance of external auditors;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
5(5)(m)	Oversee whether the proceeds raised through Initial public Offering(IPO) or Repeat public Offering(RPO) or Rights Share offer have brrn utilized as per the purpose stated in relevent offer document or prospectus approved by the Commission:			N/A
5(6)(a)	**Reporting of the Audit Committee**			
5(6)	**Reporting to the Board of Directors**			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board.	✓		
5(6)(a)(ii)	The Audit Committee shall immediately report to the Board of Directors on the following findings, if any:-			
5(6)(a)(ii)(a)	report on conflicts of interests;			No such Incidence arose
5(6)(a)(ii)(b)	suspected or presumed fraud or irregularity or material defect identified in the internal internal audit and compliance process or in the financial statements;control system;			No such Incidence arose
5(6)(a)(ii)(c)	suspected infringement of laws,regulatory compliances including securities related laws, rules and regulations;			No such Incidence arose
5(6)(a)(ii)(d)	any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;			No such Incidence arose
5(6)(b)	Reporting to the Authorities:-			
	If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.			No such reportable incidence arose
5(7)	Reporting to the Shareholders and General Investors			
	Report on activities carried out by the Audit Committee, including any report made to the Board under condition 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
6.	**Nomination and remuneration Committee(NRC).-**	Formed in Board of Directors meeting held on 23rd September, 2018		
6(1)	**Responsibility to the Board of Directors**			
6(1)(a)	The company shall have a Nomination and Remuneration Committee (NRC) as a sub-committee of the Board;	✓		
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;			NRC has taken steps to comply this matter
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).			
6(2)	**Constitution of the NRC**			
6(2)(a)	The Committee shall comprise of at least three members including an independent director;	✓		
6(2)(b)	All member of the Committee shall be non-executive directors;	✓		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	✓		
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;			
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;			No such case has arose after formation of NRC
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion form such external expert and/or member(s) of staff shall be required or valuable for the Committee;			No such case in arose after formation of NRC
6(2)(g)	The company secretary shall act as the secretary of the Committee;	✓		
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;			No such case in arose after formation of NRC

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.			No such things happened after formation of NRC
6(3)	**Chairperson of the NRC**			
6(3)(a)	The Board shall select 1(one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	✓		
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;			
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders:		✓	Will attend in upcoming AGM.
6(4)	**Meeting of the NRC**			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;			No such case in arose after formation of NRC
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;			No such case in arose after formation of NRC
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);			No such case in arise after formation of NRC
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.			No such case in arose after formation of NRC
6(5)	**Role of the NRC**			The NRC has taken steps to comply the role of NRC as set by BSEC Corporate Governance Code
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;			
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board:			

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
6(5)(b)(i)	Formulating the ceiteria for determining qualifications, positive atteibutes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:			
6(5)(b)(i)(a)	The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;			
6(5)(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and			
6(5)(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;			
6(5)(b)(ii)	Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity,educational background and nationality;			
6(5)(b)(iii)	Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the ceiteria laid down, and recommend their appointment and removal to the Board;			
6(5)(b)(iv)	Formulating the criteria for evaluation of performance of independent directors and the Board;			
6(5)(b)(v)	Indentifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;			
6(5)(b)(vi)	Developing, recommending and reviewing annually the company's human resources and training policies;			
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	✓		
7.	**External or Statutory Auditors**			
7(1)	The issuer shall not engage its external or statutory auditors to perform the following servicesof the company, namely :--			
7(1) (i)	Appraisal or valuation services or fairness opinions;	✓		
7 (1) (ii)	Financial information system design and implementation;	✓		
7 (1) (iii)	Book-keeping or other services related to the accounting records or financial statement;	✓		

CORPORATE GOVERNANCE

Annexure-1
Compliance Report

Condition No.	Title	Complied	Not Complied	Remarks (if any)
7 (1) (iv)	Broker –dealer services;	✓		
7 (1) (v)	Actuarial services;	✓		
7 (1) (vi)	Internal audit services or special audit services;	✓		
7 (1) (vii)	Any services that the Audit Committee determines.	✓		
7 (1) (viii)	Audit or certifiaction services on compliance of corporate governance as required under condition No.9(1);	✓		
7 (1) (ix)	Any other service that creates conflict of interest	✓		
7(2)	No Partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenureof their audit assignment of that company; his or her family members also shall not hold ant shares in the said company:	✓		
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	✓		
8.	**Maintaining a website by the Company.-**			
8(1)	The Company shall have an official website linked with the website of the stock exchange.	✓		
8(2)	The company shall keep the website functional from the date of listing.	✓		
8(3)	The company shall make available the detailed disclosures on its website as required under the regulations of the concerned stock exchange(s)	✓		
9.	**Reporting and Compliance of Corporate Governance.-**			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	✓		Required certification has been obtained from "PODDER & ASSOCIATES" Cost & Management Accountants for the year ended 30th June 2018.
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the Shareholders in the annual general meeting.		✓	Board recommended the Professional for due appointment by the Shareholders in 17th AGM on 9th December, 2018
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	✓		

PODDER & ASSOCIATES
Cost and Management Accountants

Report to the Shareholders of BEACON PHARMACEUTICALS LTD. on compliance on the Corporate Governance Code.

We have examined the compliance status to the Corporate Governance Code by BEACON PHARMACEUTICALS LTD. for the year ended on June 30, 2018. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, Dated: 3 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

(a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission Except under conditions number 6(3)(c) & 9(2).

(b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;

(c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws ; and

(d) The governance of the company is satisfactory.

For Podder & Associates

Jayanta Kumer Podder
Cost & Management Accountants

Place: Dhaka
Dated:28th October 2018

6/A/1 (Ground Floor), Segun Bagicha, Dhaka-1000. Phone : 02-57160360, 02-57160425, E-mail: info@thepodders.com, Web: www.thepodders.com



Bukof

Butamirate Citrate INN 50 mg SR Tablet & 100 ml Syrup

Remedy for all types of cough

- Pre- & post-operative cough in surgery
- Cough caused by bronchoscopy
- Cough due to acute LRTI
- Chronic cough of any etiology



Orange flavored Syrup for kids



*100 ml syrup (7.5 mg/5 ml)

For Adult Available as:



*50 mg SR Tablet

BEACON® Pharmaceuticals Limited
Light for life

Directors' Responsibilities
for the Financial Statements



Directors' Responsibilities
for the Financial Statements

The Directors are responsible for preparing the annual report and financial statements in accdance with the Company's Act.1994, Securities and Exchange Commission Rules 1987, Bangladesh Financial Reporting Standards (BFRS) and other applicable laws and regulations.

The Company's Act. 1994 requires Directors to ensure that the Company keeps proper books of accounts of all transactions and prepares financial statements that give a true and fair view of the state of the Company's affairs and of the profit for the year.

The Directors are also required to ensure that the financial statements have been prepared and presented in accordance with the International Financial Reporting Standards (IFRS) and the Bangladesh Financial Reporting Standards (BFRS) as applicable in Bangladesh and provided the information required by the Company's Act 1994, Securities and Exchange Ordinance 1969, Securities and Exchange Commission Rules 1987 and the regulations of Dhaka / Chittagong Stock Exchanges. They are also responsible for taking reasonable measures to safeguard the assets of the Company, and in that context to have proper regard to the establishment of the appropriate system of internal control with a view to preventing and detecting fraudulent activities and other irregularities.

The Directors are of the view that these financial statements have been prepared under the generally accepted accounting principles and in accordance with the Bangladesh Accounting Standards as laid down by the Institute of Chartered Accountants of Bangladesh.

Directors endeavor to ensure that the Company maintains sufficient records to be able to disclose, with reasonable accuracy, the financial position of the Company and to be able to ensure that the financial statement of the Company meet with the requirement of the Company's Act 1994, Bangladesh Accounting Standards and the regulations of the Dhaka / Chittagong Stock Exchanges.

The Directors have a reasonable expectation, after making enquiries and following a review of the Company's plan for the ensuing year including cash flows and borrowing facilities, that the Company has adequate resources to continue in operational existence for the foreseeable future, and therefore continues to adopt the going concern basis in preparing the accounts.
M/S. Shafiq Basak & Co., Chartered Accountants, Auditors of the Company have examined the financial statements made available by the Board of the Directors together with relevant financial record, related data, minutes of the Shareholders and Directors meeting and expressed their opinion in their report.

By order of the Board,


BEACON Pharmaceuticals Ltd.,



Md. Ebadul Karim
Managing Director

AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2018



FINANCIAL STATEMENTS



INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF BEACON PHARMACEUTICALS LIMITED

Report on the Financial Statement

We have audited the accompanying financial statements of BEACON PHARMACEUTICALS LIMITED comprising of Statement of Financial Position at 30th June, 2018 and Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year ended to that date.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards (IFRSs) and International Accounting Standards (IASs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA) as adopted in Bangladesh. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedure that are appropriate in the circumstance, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter:

The company has not properly complied with section 234 (1)(b) of Bangladesh Labor Law 2006 (as amended in 2013) of WPPF rules regarding distribution of the fund and interest payable thereon.

Opinion

In our opinion, the financial statements give a true and fair view of the financial position of the Company as at 30 June 2018, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF BEACON PHARMACEUTICALS LIMITED

Report on Other Legal and Regulatory Requirements

In accordance with the requirements of the Companies Act 1994 and the Securities and Exchange Rules 1987, we report that:

a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;

b) In our opinion, proper books of account as required by law have been kept by the company so far as it appeared from our examination of those books;

c) The Company's Statement of Financial Position, Statement of Profit or Loss and Comprehensive Income and Statement of Cash Flows dealt with by this report are in agreement with the books of account; and

d) The expenditures incurred were for the purpose of the Company's business.

Dated, Dhaka

22 October 2018

(Shafiq Basak & Co.)

Chartered Accountants

BEACON PHARMACEUTICALS LIMITED

STATEMENT OF FINANCIAL POSITION

AS AT JUNE 30, 2018

Particulars	Notes	Amount in Taka 30 June 2018	Amount in Taka 30 June 2017
ASSETS:			
I. Non-Current Assets:		**2,508,372,310**	**2,681,258,044**
Property, Plant & Equipments	4.00	2,216,498,633	2,069,459,838
Capital Work in Progress	5.00	290,111,576	608,876,716
Investment in Shares	6.00	1,762,101	2,921,490
II. Current Assets:		**2,400,038,430**	**2,424,721,610**
Inventories	7.00	1,021,536,717	1,088,458,711
Accounts Receivable	8.00	436,836,128	298,602,388
Advance, Deposit & Pre-payments	9.00	458,120,316	344,209,826
Short Term Investment	10.00	339,209,477	444,650,345
Deferred Tax Assets	11.00	46,733,455	15,157,262
Investment in FDR	12.00	12,933,556	-
Cash & Cash Equivalents	13.00	84,668,781	233,643,078
Total Assets:		**4,908,410,740**	**5,105,979,654**
EQUITY & LIABILITIES			
III. Shareholders' Equity:		**3,000,743,908**	**2,991,300,290**
Share Capital	14.00	2,310,000,000	2,310,000,000
Reserve and Surplus	15.00	285,215,467	304,166,101
Available for Sale Reserve		(915,323)	244,066
Retained Earnings	16.00	406,443,764	376,890,123
IV. Non-Current Liabilities:		**575,000,582**	**976,649,730**
Long Term Loan	17.00	575,000,582	976,649,730
V. Current Liabilities:		**1,332,666,250**	**1,138,029,634**
Current Portion of Long Term Loan	18.00	308,193,645	25,811,644
Short Term Loan	19.00	903,370,275	919,405,055
Share Application Money Refundable	20.00	4,323,613	4,323,613
Accounts Payables	21.00	51,206,139	75,489,811
Accrued Expenses	22.00	50,069,081	71,180,794
VAT Payable	23.00	13,243,674	6,438,375
Liabilities for EWF & WPPF	24.00	22,779,093	19,352,404
Provision for Employee's Provident Fund	25.00	6,352,182	10,966,918
Provision for Gratuity	26.00	28,336,371	16,053,742
Tax Payable/(Refundable)	27.00	(89,671,334)	(28,035,719)
Dividend Payable	28.00	34,463,510	17,042,997
TOTAL EQUITY & LIABILITIES		**4,908,410,740**	**5,105,979,654**
Net Asset Value (NAV)/Share		**12.99**	**12.95**
Par Value (Tk.)		**10.00**	**10.00**

The annexed notes 01 to 45 form an integral part of these financial statements. These financial statements were approved by the Board of Directors on 21-10-2018 and signed on its behalf by:

Company Secretary

Managing Director

Nurun Nahar Karim
Chairman

Signed in terms of our separate report of even date annexed.
Dated, Dhaka
22 October 2018

(Shafiq Basak & Co.)
Chartered Accountants

BEACON PHARMACEUTICALS LIMITED

Statement of Profit & Loss and Other Comprehensive Income

For the year ended 30 June, 2018

Particulars	Notes	Amount in Taka 30 June 2018	Amount in Taka 30 June 2017
Net Turnover	29.00	3,760,786,106	2,948,456,509
Less: Cost of Goods Sold	30.00	1,927,331,673	1,484,623,696
Gross Profit		**1,833,454,433**	**1,463,832,813**
Less: Operating Expenses:			
Administrative Expenses	31.00	239,590,025	154,283,443
Marketing, Selling & Distribution Expenses	32.00	1,324,256,067	1,042,274,331
Total Operating Expenses		**1,563,846,092**	**1,196,557,774**
Operating Profit		**269,608,341**	**267,275,039**
Less: Financial Expenses	33.00	138,082,326	147,375,018
Net Profit after Financial Expenses		**131,526,015**	**119,900,021**
Income from Other Sources	34.00	811,526	1,790,763
Net Profit before contribution to WPPF		**132,337,541**	**121,690,784**
Less: Contribution to WPPF	35.00	6,301,788	5,794,799
Net Profit before Tax		**126,035,753**	**115,895,985**
Less: Provision for Income Tax		31,508,938	28,973,996
Add: Deferred Tax Income		31,576,193	16,812,652
Net profit after tax for the year		**126,103,008**	**103,734,641**
Other Comprehensive Income		-	-
Net profit after tax for the year		**126,103,008**	**103,734,641**
Item that may be reclassified to profit or loss:			
Unrealized Profit (loss) on quoted shares	36.00	(1,159,389)	975,875
Total comprehensive income for the year		**124,943,619**	**104,710,516**
No. of Shares		**231,000,000**	**231,000,000**
Earning Per Share		**0.55**	**0.45**

The annexed notes 01 to 45 form an integral part of these financial statements. These financial statements were approved by the Board of Directors on 21-10-2018 and signed on its behalf by:

Company Secretary

Managing Director

Nurun Nahar Karim
Chairman

Signed in terms of our separate report of even date annexed.
Dated, Dhaka
22 October 2018

(Shafiq Basak & Co.)
Chartered Accountants

BEACON PHARMACEUTICALS LIMITED

Statement of Changes in Equity

For the year ended 30 June, 2018

Amount in Taka

Particulars	Share Capital	Revaluation Reserve Reserve	Tax Holiday Reserve	Available for Sale Reserve	Retained earnings	Total Equity
Year 2017-2018:						
Balance at the beginning of the year	**2,310,000,000**	**298,663,002**	**5,503,099**	**244,066**	**376,890,123**	**2,991,300,290**
Net Profit transferred from Income Statement	-	-	-	-	126,103,008	126,103,008
Unrealized gain on quoted shares	-	-	-	(1,159,389)	-	(1,159,389)
Revaluation Reserve adjustment	-	(25,267,512)	-	-	25,267,512	-
Deferred Tax on Revaluation Adj.	-	6,316,878	-	-	(6,316,878)	-
Cash Dividend	-	-	-	-	(115,500,000)	(115,500,000)
Balance at the end of the year	**2,310,000,000**	**279,712,369**	**5,503,099**	**(915,323)**	**406,443,764**	**3,000,743,909**

Amount in Taka

Particulars	Share Capital	Revaluation Reserve Reserve	Tax Holiday Reserve	Available for Sale Reserve	Retained earnings	Total Equity
Year 2016-2017:						
Balance at the beginning of the year	**2,310,000,000**	**317,613,636**	**5,503,099**	**(731,809)**	**369,704,848**	**3,002,089,774**
Net Profit transferred from Income Statement	-	-	-	-	103,734,641	103,734,641
Unrealized gain on quoted shares	-	-	-	975,875	-	975,875
Revaluation Reserve adjustment	-	(25,267,512)	-	-	25,267,512	-
Deferred Tax on Revaluation Adj.	-	6,316,878	-	-	(6,316,878)	-
Cash Dividend	-	-	-	-	(115,500,000)	(115,500,000)
Balance at the end of the year	**2,310,000,000**	**298,663,002**	**5,503,099**	**244,066**	**376,890,123**	**2,991,300,290**

The annexed notes 01 to 45 form an integral part of these financial statements. These financial statements were approved by the Board of Directors on 21-10-2018 and signed on its behalf by:

Company Secretary

Managing Director

Nurun Nahar Karim
Chairman

Signed in terms of our separate report of even date annexed.
Dated, Dhaka
22 October 2018

(Shafiq Basak & Co.)
Chartered Accountants

BEACON PHARMACEUTICALS LTD.

Statement of Cash Flows

For the year ended 30 June, 2018

Particulars	Notes	Amount in Taka 30 June 2018	Amount in Taka 30 June 2017
A. Cash Flows from Operating Activities			
Collection from Customers		3,622,552,366	2,972,865,461
Cash paid to Suppliers & others		(3,159,436,202)	(1,844,671,641)
Interest paid		(136,411,113)	(147,375,018)
Income tax paid		(27,000,000)	-
Net Cash Generated from Operations		**299,705,051**	**980,818,802**
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant and Equipment		(323,663,936)	(623,927,873)
Short term Investment Received		105,440,868	(99,062,188)
Investment in FDR		(12,825,800)	-
Interest and Other Received		811,526	1,790,763
Net Cash used in Investing Activities		**(230,237,342)**	**(721,199,298)**
C. Cash Flows from Financing Activities			
Dividend paid		(83,140,078)	(82,975,895)
Long term Loan Received/(Paid)		(119,267,147)	113,509,080
Short term loan Paid		(16,034,780)	(161,494,450)
Share Application Money paid		-	(10,000)
Net Cash from/(used in) Financing Activities		**(218,442,005)**	**(130,971,265)**
D. Net Increase/(decrease) in Cash and Cash Equivalents (A+B+C)		**(148,974,297)**	**128,648,239**
E. Opening Cash and Cash Equivalents		**233,643,078**	**104,994,839**
F. Closing Cash and Cash Equivalents (D+E)		**84,668,781**	**233,643,078**
Net Operating Cash Flows		**1.30**	**4.25**

The annexed notes 01 to 45 form an integral part of these financial statements. These financial statements were approved by the Board of Directors on 21-10-2018 and signed on its behalf by:

Company Secretary

Managing Director

Nurun Nahar Karim
Chairman

Signed in terms of our separate report of even date annexed.
Dated, Dhaka
25 October 2017

(Shafiq Basak & Co.)
Chartered Accountants

1.00 BACKGROUND AND ACTIVITIES OF THE COMPANY:

1.01 Background of the Company:

The company was incorporated on 12 September 2001 as a Private Limited Company and subsequently converted into Public Limited Company on February 25, 2008 under the Companies Act, 1994 vide registration No. C-43991(531)/2001 dated 12 September 2001. The Company went for Initial Public Offering (IPO) in 2010. The company is a publicly traded company and is listed with Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited since the year 2010.

1.02 Address of the Registered and Corporate Office:

The registered office of the company is located at its factory premises at Kathali, Bhaluka, Mymensingh and corporate office address is located at 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223.

1.03 Nature of Business Activities:

The company is engaged in manufacture and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) Fluids, Active Pharmaceuticals Ingredients (APLs), Bio-tech products and genetic engineering products which the company sales in the local markets as well as international markets. The company also provides contract manufacturing and tool manufacturing services.

1.04 Production Unit:

Production unit of the company is situated at Kathali, Bhaluka, Mymensingh.

2.00 SIGNIFICANT ACCOUNTING POLICIES:

2.01 Basis of Preparation and Presentation of the Financial Statements:

The Financial Statements have been prepared and the disclosures of information made in accordance with the requirements of the Companies Act 1994, the Securities and Exchange Rules 1987, the Listing Regulations of Dhaka Stock Exchange as applicable and IASs adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), International Financial Reporting Standard (IFRS) as applicable to the company. The Statement of Profit or Loss And Other Comprehensive Income have been prepared according to IAS 1 'Presentation of Financial Statements' based on accrual basis of accounting consistently applied following going concern assumption under generally accepted accounting principles and practices in Bangladesh. Statement of Cash Flows has been prepared on direct method in accordance with IAS 7.

2.02 Accounting Convention and Assumption:

The financial statements have been prepared under the historical cost convention as modified to include the revaluation of certain fixed assets which are stated at revalued amount. Accordingly, historical cost is employed to determine the monetary amounts at which the elements of the financial statements are to be recognized and carried in the statement of financial position and statement of profit or loss and other comprehensive income.

2.03 Principle of Accounting Policies:

The specific accounting policies have been selected and applied by the company's management for significant transactions and events that have a material effect within the Framework for the preparation and presentation of Financial Statements. Financial Statements have been prepared and presented in compliance with applicable IASs. Previous year's figures were re-arranged where necessary to conform current years' presentation. There were no significant changes in the accounting policies and valuation policies affecting the financial position and performance of the company. However, changes (as applicable)

made to the presentation are explained into the note for the respective items.

2.04 Application of accounting Standards

The following IASs and IFRSs are applicable to the financial statements for the year under review:

IAS 1 Presentation of Financial Statements
IAS 2 Inventories
IAS 7 Cash Flow Statements
IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10 Events after the Balance Sheet Date
IAS 12 Income Tax
IAS 16 Properties, Plant and Equipment
IAS 19 Employee Benefits
IAS 21 The Effects of Changes of Foreign Exchange Rates
IAS 23 Borrowing Costs
IAS 24 Related Parties Disclosure
IAS 33 Earnings Per Share
IAS 36 Impairment of Assets
IAS 37 Provisions, Contingent Liabilities and Contingent Assets
IAS 39 Financial Instruments: Recognition and Measurement
IFRS 15 Revenue from Contracts with Customers
IFRS 9 Financial Instruments
IFRS 13 Fair Value Measurements

2.05 Valuation of Inventories:

Inventories are stated at the lower of cost or net realizable value in compliance with the requirements of Para 21 and 25 of IAS 2.

Category of Stocks		Basis of Valuation
Raw Materials and Packing Materials	:	Moving average (weighted) cost
Work in Process	:	Actual Cost
Finished Goods	:	Actual Cost
Others	:	Actual Cost

Cost comprises of the value of materials and attributable direct labor, depreciation and production overheads. The management has conducted annual physical verification of inventories on the closing date of business as on 30 June, 2018 made valuation thereof on the basis stated above.

2.06 Statement of Cash Flows:

Statement of Cash Flow is prepared principally in accordance with IAS 7 'Statement of Cash Flows' and the cash flows from operating activities have been presented under direct method as required by the Securities and Exchange Rules 1987 and Considering the provisions that "Enterprises are Encouraged to Report Cash Flow From Operating Activities Using the Direct Method".

2.07 Accounting Policies, Changes in Accounting Estimates and Errors:

As per IAS 8 The preparation of financial Statements in conformity with the International Accounting Standards requires management to make judgment to estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statement.

During the year under review no remarkable change were made that make judgment to estimates and assumptions that affect the application of accounting policies reported amounts of assets, liabilities, income and expenses.

2.08 Taxation:

2.08.01 Current Tax:

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. The company makes provision for income tax as per requirement of the Income Tax Ordinance 1984. The applicable tax rate of the Company is 25% or 0.60 percent of Gross Receipt whichever is higher as per provision of section 82C of the Income Tax Ordinance 1984. Income tax return of the company for the assessment year 2016-2017 has not yet been assessed as such, no adjustments is made for any under/over provision of tax.

Deferred Tax:

During the year provision for Deferred Tax as per requirement by IAS 12 has been accounted for in the financial statements. Deferred tax is recognized using the balance sheet method. Deferred tax arises due to temporary difference deductible or taxable for the events or transactions recognized in the statement of profit or loss and other comprehensive income. A temporary difference is the difference between the carrying amounts of assets and liabilities and its tax base amount in the statement of financial position. Deferred tax asset or liability is the amount of income tax recoverable or payable in future period(s) recognized in the current period. The deferred tax asset/income or liability/expense do not create a legal liability/recoverability to and from the income tax authority. Deferred tax also arises due to revaluation of property, plant and equipment. The resulting impact of deferred tax assets/liabilities on revaluation surplus is included in the statement of changes in equity.

2.09 Property, Plant and Equipment:

Item of property, plant & equipment is recognized in accordance with IAS 16 Property, Plant and Equipment where it is probable that future economic benefits will flow to the entity and their cost can be measured reliably.

2.09.01 Measurement and recognition:

An item of property, plant & equipment qualifying for recognition is initially measured at its cost. Cost comprises: Purchase price, including all non recoverable duties and taxes but net off discount; and costs directly attributable to bringing the assets to the location and condition necessary for it to be capable of operating in the manner intended by the management.

2.09.02 Subsequent costs:

Repairs and maintenance expenditure is recognized as expenditure when incurred. Replacement parts are capitalized, provided that the original cost of the items they replace is derecognized.

2.09.03 Disposal of property, plant and equipment:

An item of property, plant and equipment is removed from the statement of financial position when it is disposed of or when no future economic benefits are expected from its use or disposal. The gain or loss on the disposal of an item of property, plant and equipment is included in the statement of income of the period in which the assets are disposed off. There were no disposals of property, plant and equipment in 2018.

2.09.04 Impairment of Assets:

In compliance with the requirements of IAS 36, Impairment of Assets, the carrying amount of non-financial assets, other than inventories are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the assets recoverable amount is estimated and impairment losses are recognized in profit and loss account. No such indication of impairment has been raised till to date.

2.09.05 Depreciation of Fixed Assets:

Depreciation is providing on Straight-line method. Depreciation is charged on additions according to para 55 of IAS 16.

The depreciation /amortization rate(s) are as follows:

Category of Fixed Assets	Rate %
Land & Land Development	0
Building	5
Vehicles	20
Electrical Installations	10
Office Equipment	10
Production Machinery & Equipment	15
Furniture & Fixture	10

2.10 Leases:

In compliance with the requirements of IAS 17 no financial and operating leases is accounted for during the year under review.

2.11 Revenue Recognition:

In compliance with the requirements of IFRS 15 Revenue, Revenue is recognized only when; Revenue receipts from customers against sales are recognized when products are dispatched to the customers, that is, when the significant risk and rewards of ownership have been transfer to the buyer recovery of the consideration is probable, the associated cost and possible return of goods can be estimated reliable and there is no continuing management involvement with the goods. Interest income is accounted for on accrual basis as per bank statement received from bank. Income is derived this year from export of finished products.

2.12 Employee Benefits (IAS 19):

The Company maintains both defined contribution plan (Provident Fund) and a retirement benefit obligation (Gratuity Fund) for its eligible permanent employees.

2.13.01 Defined Benefit Plans (Provident Fund):

Defined contribution plan is a post-employment benefit plan under which the Company provides benefits for

all of its permanent employees. The recognized Employees' Provident Fund is being considered as defined contribution plan as it meets the recognition criteria specified for this purpose. All permanent employees contribute 10% of their basic salary to the provident fund and the Company also makes equal contribution. This fund is recognized by the National Board of Revenue (NBR), under the First Schedule, Part B of Income Tax Ordinance 1984.

2.13.02 Retirement Benefit Obligation (Gratuity Fund):

The Company has a gratuity scheme, which covers all of its permanent employees. The gratuity is payable when the employees have completed minimum five years of service. Employees, leaving the employments after five completed years shall receive one month's terminal basic for each completed year.

2.13.03 Contribution to workers' profit participation fund:

As per section 234(1)(b) of Bangladesh Labor Act 2006 (as amended in 2013) 5% of the net profit of each year, not later than nine (9) months from the close of that period, is required to be transferred to the Fund, the proportion of the payment to the Participation Fund and the Welfare Fund being 80:10. The remaining 10% of the amount of net profit shall be paid by the Company to the Workers' Welfare Foundation Fund, as formed under the provision of the Bangladesh Worker's Welfare Foundation Act, 2006. Of the 80% being transferred to the participation fund, two-third has to be distributed in equal proportions to all the members (beneficiary) of the fund in cash and one-third has to be invested in accordance with the manner as stated in section 242 of that Act.

2.14 Financial Instruments:

2.14.01 Initial recognition and subsequent measurement:

A financial instrument is any contract that gives rise to financial assets of one entity and a financial liability or equity instrument of another entity. Financial assets include available for sale assets, held to maturity assets, held for trading, loans and receivable and cash and cash equivalent. Financial Liabilities include borrowings, others financing and bank loans and accounts payables.

2.14.02 Recognition:

An entity recognizes financial assets or liabilities in its statement of financial position when and only when the entity becomes a party to the contractual provision of the instrument.

2.14.03 Subsequent Measurement:

Asset Category	Description	Measurement after initial recognition	Recognition
Available for sale Financial assets: 1) Investment in marketable securities	Financial assets that are either electively designated into the category or do not fall into any other category	Fair Value	1) realized gain loss/ dividend income/Interest income to statements of comprehensive income 2) Unrealized gain-loss to Statement of Comprehensive Income.

Asset Category	Description	Measurement after initial recognition	Recognition
Loans and Receivables, 1) Trade Receivables 2) Others receivables	unquoted financial assets with fixed or determinable payments.	Authorized Cost	Realized gain loss/ interest income foreign currency gain loss to statement of Comprehensive Income
Financial liabilities at cost /amortized cost . 1)Short term loan , 2)Trade creditors , 3) Others payable	All financial liabilities other than those at fair value though profit and loss	Authorized Cost	Realized gain loss/ interest income foreign currency gain loss to statement of Comprehensive Income

2.15 The Effects of Changes of Foreign Exchange Rates:

Foreign currency transactions are recorded at the rates applicable on the date of transaction in accordance with IAS-21 (The Effects of Changes in Foreign Exchange Rates). Gains or losses out of foreign currency transactions are charged/credited to the profit and loss account whenever arises. This year the company made transactions in foreign currency for import of machineries which has been accounted for properly.

2.16 Credit Risk:

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The senior management of Beacon Pharmaceuticals Limited carefully manages its exposure to credit risk. Credit exposures arise principally in receivables from customers into Beacon Pharmaceuticals Limited asset portfolio. The credit risk management and control are controlled through the credit policies of Beacon Pharmaceuticals Limited which are updated regularly. The company is also exposed to other credit risks arising from balances with banks which are controlled through board approved counterparty limits.

2.17 Liquidity Risk:

Liquidity risk is defined as the risk that the Company will not be able to settle or meet its obligations on time or at a reasonable price. The Company's approach toward managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date.

2.18 Interest Rate Risk:

Interest rate risk is the risk that company faces due to unfavorable movement in the interest rates. Changes in the government's monetary policy, along with increased demand for loans/investments tend to increase the interest rates. Such rises in interest rates mostly affect companies having floating rate loans or companies investing in debt securities.

2.19 Exchange Rate Risk:

Exchange rate risk occurs due to changes in exchange rates. As the company imports equipment from abroad, unfavorable volatility or currency fluctuation may affect the profitability of the Company. When exchange rate increase against local currency, opportunity arises for generating more profit.

2.2 Market Risks:

Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the company. Mostly, the risk arises from falling demand for the product or service which would harm the performance of the company. On the other hand, strong marketing and brand management would help the company increase their customer base.

2.21 Borrowing Costs:

In compliance with the requirements of IAS-23 'Borrowing Costs' borrowing costs of operational period on short-term loan and overdraft facilities from Banks was charged off as revenue expenditure as those were incurred.

2.22 Related Parties disclosure

In compliance with the requirements of IAS 24, the company carried out a number of transactions with related parties in the normal course of business. Related party disclosures have been made in a separate note to the accounts.

2.23 Earning per Shares:

2.23.01 Basic Earnings Per Share

The company calculates Basic earning of share (EPS) in according with IAS 33 'Earning per Shares' which has been shown on the face of Income Statement. The same has been calculated dividing surplus available for ordinary shareholders by weighted number of ordinary shares outstanding at the end of the year.

2.23.02 Diluted Earnings Per Share:

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the affects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary share during the relevant periods.

2.24 Provision:

The preparation of financial statements in conformity with International Accounting Standards (IAS) 37 provides that, Provisions, Contingent Liabilities and Contingent Assets requires management to make estimates and assumption that affect the reported amounts of revenues and expense, assets and liabilities, and the disclosure requirements for contingent assets and liabilities during and at the date of the financial statements.

In accordance with the guidelines as prescribed by IAS 37 provisions were recognized in the following situations. When the company has represent obligation as a result of past event. When it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation ; and realizable estimate cab be made of the amount of the obligation.

Provisions in the financial statements at an appropriate level are not done with regard to an adequate provision of risks and uncertainties. An amount recorded as a provision represents the best estimate of the probable expenditure required fulfilling the current obligation on the balance sheet date.

2.25 Intangible Assets:

In compliance with requirements of IAS 38 intangible assets are usually absorbed as revenue charges as and when incurred. The Company has no intangible assets written off during the year under review.

2.26 Cash and Cash Equivalents:

Cash and Cash Equivalents include cash in hand, cash at banks, etc. which are available for use by the company without any restrictions. There is an insignificant risk of change in value of the same.

2.27 Trade and Other Payable:

Liabilities are recorded at the amount payable for settlement in respect of goods and services received by the company.

2.28 Repairs and Maintenance Charges:

These are usually charged out as revenue expenditure in the period in which it is incurred.

2.29 Bad and doubtful debts:

No provision for bad and doubtful debts has been made since sales/export are realizable.

2.30 Promotional Expenses:

All costs associated with promotional activities are charged in the year those were incurred like sample issued.

2.31 Insurance Coverage:

Fixed Assets and Inventories of the company are covered by general insurance policies.

3.00 COMPLIANCE AND OTHERS:

3.01 Compliance with Local Laws:

The Financial Statements have been prepared in compliance with requirements of the Companies Act 1994, the Securities and Exchange Rules 1987 and other relevant local laws and rules.

3.02 Compliance with International Accounting Standards (IAS):

The Financial Statements have been prepared in compliance with requirements of IAS/IFRS as adopted in Bangladesh by the Institute of Chartered Accounts of Bangladesh (ICAB).

3.03 Reporting Currency and Level of Precision:

The figures in the Financial Statements represent Bangladesh Currency (Taka), which have been rounded off to the nearest Taka except where indicated otherwise.

3.04 Comparative Information:

Comparative information have been disclosed in respect of the year 2017 for all numerical information in the Financial Statements and also for the narrative and descriptive information when it is relevant for understanding of the current period's Financial Statements.

3.05 Events after the reporting period:

In compliance with the requirements of IAS-10 "Events after the Reporting Period" post statement of financial position events that provide additional information about the Company's position at the statement of financial position date are reflected in the financial statements and events after the statement of financial position date that are not adjusting events are disclosed in the notes when material.

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017

3.06 Directors' responsibility statement:

The Board of Directors takes the responsibility for the preparation and fair presentation of these financial statements.

3.07 Reporting Period:

The financial period of the company covers year from 01 July 2017 to 30 June 2018 followed consistently.

3.08 Approval of Financial Statement:

The financial statements have been approved by the Board of Directors as on 21 October 2018.

04.00 PROPERTY PLANT & EQUIPMENT: TK. 2,216,498,633

A) Cost:			
Opening Balance		4,180,593,419	3,401,685,777
Add: Addition during the year		642,429,076	778,907,642
Less: Adjustment during the year		-	-
Closing Balance (A)		**4,823,022,495**	**4,180,593,419**
B) Accumulated Depreciation			
Opening Balance		2,111,133,581	1,716,104,224
Add: Addition during the year		495,390,280	395,029,357
Less: Adjustment during the year		-	-
Closing Balance (B)		**2,606,523,861**	**2,111,133,581**
Written Down Value (A-B)		**2,216,498,633**	**2,069,459,838**

Details of Fixed Assets Schedule are given in Annexure-A

05.00 CAPITAL WORK IN PROGRESS: TK. 290,111,576

Opening Balance		608,876,716	763,856,485
Add: Addition during the year	**Notes-5.01**	121,564,770	226,939,342
		730,441,486	990,795,827
Less: Transfer to property plant & equipment	**Notes-5.02**	440,329,910	381,919,111
Closing Balance		**290,111,576**	**608,876,716**

5.01 Breakup of Capital Work in Progress addition during the year: Tk. 121,564,770

Production Machinery & Equipment	-	16,773,931
Quality Control Apparatus & Equipment	-	1,000
Engineering Machinery Equipment	-	11,473
Purified Water Treatment Installation	-	35,585,998
Dock Leveler Installation	-	5,600
General Production Building-1	9,978,489	5,191,644

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	General Production Building-2		85,632,681	82,846,736
	VIP Staff Quarter		1,985,235	3,230,448
	Staff Dormitory		541,237	1,376,226
	R & D Building		1,402,483	1,084,928
	Parenterial Building		22,024,645	80,831,358
			121,564,770	**226,939,342**
5.02	**Breakup of Capital Work in Progress transfer to property plant & equipment during the year: Tk. 440,329,910**			
	Production Machinery & Equipment		65,390,300	271,618,240
	Quality Control Apparatus & Equipment		-	7,252,102
	Engineering Machinery Equipment		-	100,887,540
	Dock Leveler Installation		-	1,027,781
	Office Equipment		-	1,133,448
	Purified Water Treatment Installation		40,508,704	-
	General Production Building-1		27,652,863	-
	General Production Building-2		241,735,131	-
	Corporate Head Office		29,938,877	-
	VIP Staff Quarter		21,669,294	-
	Staff Dormitory		13,434,741	-
			440,329,910	**381,919,111**
06.00	**INVESTMENT IN SHARE: TK. 1,762,101**			
	Opening Balance		2,921,490	1,945,615
	Add: Unrealized gain or (Loss)		(1,159,389)	975,875
	Closing Balance		**1,762,101**	**2,921,490**

Breakup of the above amount is given below:

Particulars	Number of Shares	Market Value		Book Value
		30 June 2018	30 June 2017	
Intech Limited	199	3,383	3,022	2,300
R N Spinning Mills Ltd.	152,932	1,758,718	2,918,468	3,855,041
Total	**153,131**	**1,762,101**	**2,921,490**	**3,857,341**

The above amount have been classified as "Available for sale " financial assets as per IAS 39 and shown at fair value of TK 1,762,101 derived from Quoted share prices as on 30-06-2018. Unrealized loss of TK 1,159,389 on the unsold shares has been recognized in the other comprehensive income.

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
07.00	**INVENTORIES: TK. 1,021,536,717**			
	Raw and Packing Materials		635,310,539	659,545,918
	Work-in-Process		135,588,281	85,102,385
	Finished Goods		226,034,317	338,227,070
	Laboratory Chemicals		24,603,580	5,583,338
	Closing Balance		**1,021,536,717**	**1,088,458,711**

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2. Cost of inventories are determined on weighted average cost basis. Physical verification of inventories was carried out by inventory team consisting management staff.

Sl. No.	Materials/Product	Unit	Quantity	Amount in Tk.
01	Raw Materials (Active)	GM	25,580	36,767,156
		KG	30,164	361,303,737
		Ltr	14	5,779,536
		MG	45	29,549
		ML	9,000	3,741,200
		Pcs	200	5,330,672
	Sub-Total			**412,951,850**
02	Raw Materials (Excipient)	GM	1,103	3,087
		KG	81,670	59,977,902
		Ltr	799	2,682,145
		ML	15,443	16,605
		Pcs	72,581,300	13,557,526
	Sub-Total			**76,237,265**
03	Primary Packaging	KG	60,648	29,462,523
		Pcs	10,064,498	53,127,847
	Sub-Total			**82,590,370**
04	Secondary Packaging	KG	11,805	618,450
		Pcs	51,757,907	62,912,604
	Sub-Total			**63,531,054**
05	Work in Process (WIP)	Pcs	2,748,434	135,588,281
	Sub-Total			**135,588,281**
06	Finished Goods	Pack	2,022,349	226,034,317
	Sub-Total			**226,034,317**

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017

07	Laboratory Chemicals (Reagent)	GM	41,620	15,082,372
		KG	860	2,096,749
		Ltr	1,582	3,475,409
		ML	9,470	3,949,050
Sub-Total				**24,603,580**
Grand-Total				**1,021,536,717**

08.00 ACCOUNTS RECEIVABLE: TK. 436,836,128

Barisal Sales Centre		18,567,901	8,180,635
Bogura Sales Centre		9,202,142	4,922,774
Chittagong Sales Centre		15,941,568	12,978,270
Maizdee/Chowmuhony Sales Centre		6,565,456	3,925,558
Comilla Sales Centre		12,846,502	7,211,202
Dhaka Sales Centre/Dhaka North		61,753,152	63,303,021
Faridpur Sales Centre		2,044,829	1,091,533
Khulna Sales Centre		6,570,578	4,510,042
Mymensingh Sales Centre		24,631,029	18,920,941
Narayangonj Sales Centre		10,696,799	7,795,005
Rajshahi Sales Centre		13,178,058	10,723,088
Rangpur Sales Centre		15,841,480	7,534,960
Sylhet Sales Centre		27,903,497	15,179,083
Cox's Bazar Sales Center		8,060,345	6,570,281
Dhaka Sales Center-Mohd. Pur Kakrail/Dhaka South		46,602,335	32,846,056
Brahman Baria Sales Centre		12,156,142	9,533,329
Feni Sales Centre		14,136,802	12,320,463
Beacon Privilege Point		56,259,060	35,089,415
Jessore Sales Centre		7,270,437	5,047,870
Dinajpur Sales Centre		10,093,356	4,154,212
Tangail Sales Centre		2,174,686	-
Receivable from Export Sales	**Note-8.01**	54,339,974	26,764,650
		436,836,128	**298,602,388**

8.01 Receivable from Export Sales: Tk. 54,339,974

Nepal	9,750,457	3,867,014
Srilanka	29,176,961	7,520,293

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Philippine		5,834,953	4,241,147
	Thailand		9,577,603	11,136,196
			54,339,974	**26,764,650**
	Aging of the above balance is given below:			
	Below 30 days		327,757,587	183,312,800
	Below 90 days		54,339,974	68,918,713
	Below 180 days		54,738,567	46,370,875
			436,836,128	**298,602,388**

i) The above receivables are considered good by the management.

ii) The above amount is receivable from customers against credit sales.

iii) No amount was due from the Directors, Managing Director and other officers of the Company and any of them or jointly with any other person.

iv) The Accounts Receivables have no securities except their personal securities.

09.00	**ADVANCE, DEPOSITS & PREMENTS: TK. 458,120,316**			
	Advance against VAT	**Note-9.01**	53,908,992	29,640,757
	Advance to employees	**Note-9.02**	6,485,238	2,600,461
	Advance for Earnest Money & Security Deposit	**Note-9.03**	41,473,750	23,702,156
	Advance against Import	**Note-9.04**	188,982,632	109,449,076
	Other Advance	**Note-9.05**	167,269,704	178,817,376
			458,120,316	**344,209,826**
09.01	**Advance against VAT Tk.: 53,908,992**			
	VAT		53,908,992	29,640,757
			53,908,992	**29,640,757**
09.02	**Advance to employees against: Tk. 64,85,238**			
	Salary		189,313	153,984
	Marketing expense		4,412,890	(356,161)
	Mobile Set		1,883,035	2,802,638
			6,485,238	**2,600,461**
09.03	**Advance for Earnest Money & Security Deposit: Tk. 4,14,73,750**			
	Earnest Money & Security Deposit - Tender		30,459,392	16,600,698
	Security Deposit - Titas Gas		10,428,218	6,515,318
	Security Deposit - Electricity		56,140	56,140
	Security Deposit - T & T Board		30,000	30,000
	Security Deposit - CDBL		500,000	500,000
			41,473,750	**23,702,156**

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
09.04	**Advance against Import: Tk. 18,89,82,632**			
	Advance Against L/C		188,982,632	109,449,076
			188,982,632	**109,449,076**
09.05	**Other Advance: Tk. 16,72,69,704**			
	Advance against Office Space		119,399,480	140,072,612
	Advance against Land		42,421,036	32,821,036
	Advance against Depot Rent		5,449,188	5,923,728
			167,269,704	**178,817,376**
	There is no aggregate amount due from Directors.			
	There is no claim against the Company, which can be acknowledged as bad debt.			
	No amount is due by the associated undertakings.			
10.00	**SHORT TERM INVESTMENT: TK. 339,209,477**			
	Beacon Glass Industries Ltd.(Renamed as MEK Auto Bricks Ltd.)		103,005,125	103,005,125
	Mujibunnesa Medical College & Hospital Ltd.		94,809,180	94,809,180
	Beacon Cephalosporin Ltd.		72,200,000	177,640,868
	Beacon Power Systems Ltd.		69,195,172	69,195,172
	Closing Balance		**339,209,477**	**444,650,345**
	The above amount represents investment made by the company with its associated Companies but the related share certificates are yet to be issued by the concerned companies.			
11.00	**DEFERRED TAX ASSETS: TK. 46,733,455**			
	Opening Balance		15,157,262	(1,655,390)
	Deferred tax (income)/ expenses		(31,576,193)	(16,812,652)
	Closing Balance		**46,733,455**	**15,157,262**
	Deferred Tax (Income)/Expenses			
	The break up is given below:			
	Carrying amount			
	Fixed Assets (Excluding Land & Land Development)		1,713,408,059	1,566,369,264
	Provision for Gratuity		(28,336,371)	(16,053,742)
			1,685,071,688	**1,550,315,522**
	Tax Base			
	Fixed Assets (Excluding Land & Land Development)		1,872,005,506	1,610,944,571
	Provision for Gratuity		-	-
			1,872,005,506	**1,610,944,571**
	Taxable /(deductible) temporary difference		**(186,933,817)**	**(60,629,049)**

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Tax rate		25%	25%
	Deferred tax (assets)/liabilities		(46,733,454)	(15,157,262)
	Less: Opening Balance		15,157,262	1,655,390
	Deferred tax(income)/expenses		**(31,576,193)**	**(16,812,652)**
12.00	**Investment in FDR Tk. 12,933,556**			
	One Bank Limited A/C:0018035004648		7,825,800	-
	Rupali Bank Limited A/C: 0014140007281		5,107,756	-
			12,933,556	-
13.00	**CASH & CASH EQUIVALENTS: TK. 84,668,781**			
	Cash in Hand	**Note-13.01**	34,901,339	22,704,127
	Cash at Bank	**Note-13.02**	49,767,442	210,938,951
			84,668,781	**233,643,078**
13.01	**Cash in Hand: Tk. 34,901,339**			
	Head Office		12,186,433	20,459,821
	Factory Office		2,931,310	706,817
	Chattagram Sales Office		1,653,302	105,000
	Mymensingh Sales Office		622,688	45,000
	Sylhet Sales Office		1,276,231	65,000
	Cumilla Sales Office		263,261	60,065
	Barishal Sales Office		1,011,574	85,000
	Faridpur Sales office		550,675	25,500
	Rangpur Sales Office		1,643,899	35,500
	Rajshahi Sales Office		1,563,097	55,000
	Narayanganj Sales Office		1,010,202	30,000
	Maizdee Sales Office		123,071	65,000
	Khulna Sales Office		505,426	55,000
	Bagura Sales Office		1,254,808	75,000
	Coxs's Bazar Sales Office		2,283,142	45,000
	Dinajpur Depot		846,648	35,500
	Dhaka North Depot		2,370,793	210,000
	Dhaka South Depot		254,478	165,000
	Feni Depot		598,477	65,000
	B. Baria Depot		133,183	15,000
	Beacon Privilege Point Depot		52,689	250,000

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Jessore Depot		463,708	50,924
	Tangail Deport		1,255,975	-
	CDC		46,269	-
			34,901,339	**22,704,127**
	Cash in hand is supported by cash custody certificate from the management.			
13.02	**Cash at Bank: Tk. 49,767,442**			
	HSBC - CD A/C. No. 001143379011		96,054	96,054
	First Security Islamic Bank Ltd. CD A/C No. 1110001246		715,378	336,717
	Janata Bank Ltd. CD A/C. No. - 1014203		1,371,411	1,790,762
	Janata Bank Ltd. CD A/C. No. - 001016781		-	-
	Shahjalal Islami Bank Ltd. AWA A/C. No. 10078		13,888	16,648
	The City Bank Ltd., Dinajpur Br. CD A/C. No. 1102358521001		5,696	5,696
	The City Bank Ltd. Narayangonj Br., CD A/C. No. 1101041263001		-	-
	The City Bank Ltd., Sylhet Br. CD A/C. No. 1102193550001		26,568	26,568
	ICB Islami Bank Ltd. Principal Br., CD A/C.No.001000200071157		85,006	86,386
	Dutch Bangla Bank Ltd. CD A/C. No. 0105110000016107		16,430,617	21,634,077
	Dutch Bangla Bank Ltd. STD A/C. No. 010511000001641		(1,113,330)	19,618,956
	Eastern Bank Ltd. STD A/C. No. 1011230071 (IPO Proceeds - BDT)		-	1,803,438
	Eastern Bank Ltd. STD A/C. No. 1013150120364 (IPO Proceeds - Euro)		-	529,551
	Eastern Bank Ltd. STD A/C. No. 1013110120344 (IPO Proceeds - USD)		-	3,713,402
	Eastern Bank Ltd. STD A/C. No. 1013120120354 (IPO Proceeds - GBP)		-	969,027
	Rupali Bank Ltd., Local Office Branch, Motijheel C/A., Dhaka. CD A/C. 89649		1,459,538	100,210,202
	Sonali Bank Ltd., Dilkusha Corporate Branch, Motijheel, Dhaka. CD A/C. 33028459		14,917	11,125
	Janata Bank Ltd., Bhaluka Branch. STD A/C. 0000131		979,393	695,283
	Janata Bank Ltd. FC A/C. 402000449		7,981,796	3,655,270
	Bank Asia Ltd. CD A/C. 004433010401		8,151	8,151
	Social Islami Bank Ltd. Cd A/C. No. 21330052331		2,161	3,312
	The City Bank Ltd., Gulshan Br. CD A/C. No. 1101029459001		-	-
	Dutch Bangla Bank Ltd., CD A/C No. 105.110.28382		5,135,422	3,414,544
	FSIB Ltd. Gulshan Br., FCA US Dollar, A/C-112 1650000001		56,467	56,467
	Estern Bank Ltd., Credit Card. A/C. No. 4698210304985413		(183,179)	(3,924)
	Bank Asia Ltd. CD A/C. 04633000196		365,277	365,277
	Commercial Bank of Ceylon PLC. A/C. # 1817000818		(629,283)	17,755,250
	Commercial Bank of Ceylon, ERQ A/C. # 1802011076		1,962,231	17,786,553
	Modhumoti Bank Ltd., CD A/C No: 110111100000174.		5,400	6,550

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Janata Bank Sundry A/Cs -70104001		(1,988,680)	1,472,308
	Rupali Bank Ltd. Sundry A/Cs		10,687,937	10,687,937
	Dutch Bangla Bank-STD-00000340		3,071,985	4,187,364
	Dutch Bangla Bank-CD-105-120-0003909		2,166,284	-
	Brac Bank Ltd. CD-150-520-1786608001		1,040,337	-
	Total		**49,767,442**	**210,938,951**

Bank balances are either reconciled or agreed with the bank statements but directly not confirmed by the banks except 4 nos. bank.

14.00 SHARE CAPITAL: TK. 2,310,000,000

Authorized Capital:

300,000,000 ordinary shares of Tk. 10 each	3,000,000,000	3,000,000,000

Issued, Subscribed and Paid-up Capital:

231,000,000 ordinary shares of Tk. 10 each fully paid up	2,310,000,000	2,310,000,000

Shareholding Position was as follows:

Category of Shareholder	30-06-2018			30-06-2017		
	No. of Share	No. of Shareholders	% of Total Shares	No. of Share	No. of Shareholders	% of Total Shares
Sponsors/Directors	69,307,800	3	30%	69,307,800	3	30%
Institutions	54,259,590	231	23%	54,259,590	399	17%
Public	107,432,610	22,459	47%	107,432,610	26,850	53%
Total	231,000,000	22,693	100%	231,000,000	27,252	100%

The Sponsors/Directors Shareholding positions of the company are as under

Name of Sponsors/Directors	Numbers of Shares	Amount in Taka	
		30 June 2018	30 June 2017
Mr. Md. Ebadul Karim	58,228,800	582,288,000	582,288,000
Mrs. Nurun Nahar Karim	4,725,000	47,250,000	47,250,000
Mr. Md Niazul Karim	6,354,000	63,540,000	63,540,000
Total	**69,307,800**	**693,078,000**	**693,078,000**

Classification of shareholders by holding

Range of Holdings	Numbers of Shareholders	No. of Shares	% of holding 2018
Less than 501 Shares	6,240	1,347,028	0.58%
501 to 5,000 Shares	13,689	17,346,371	7.51%
5001 to 10,000 Shares	1,269	9,700,614	4.20%
10,001 to 20,000 Shares	690	9,934,699	4.30%
20,001 to 30,000 Shares	274	6,873,120	2.98%

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017

Range of Holdings	Numbers of Shareholders	No. of Shares	% of holding 2018
30,001 to 40,000 Shares	111	3,880,521	1.68%
40,001 to 50,000 Shares	73	3,408,160	1.48%
50,001 to 100,000 Shares	181	12,898,398	5.58%
100,001 to 1,000,000 Shares	146	36,214,777	15.67%
Above 1,000,000 Shares	20	129,396,312	56.02%
Total	**22,693**	**231,000,000**	**100%**

15.00 RESERVE & SURPLUS: TK. 285,215,467

Revaluation Reserve	Note-15.01	279,712,368	298,663,002
Tax Holiday Reserve	Note-15.02	5,503,099	5,503,099
Closing Balance		**285,215,467**	**304,166,101**

15.01 Revaluation Reserve : Tk. 279,712,368

Revaluation reserve has been created out by the amount of revaluation surplus of fixed assets. Details are shown below:

Particulars	Revaluation Surplus as on 01.07.2017	Deferred tax on Revaluation Surplus	Depreciation adjustment	Deferred tax on Depreciation Adjustment	Revaluation Reserve as on 30-06-2018
Land & Land Development	168,084,972	-	-	-	168,084,972
Building	13,397,116	-	1,072,484	268,121	12,592,753
Vehicles	24,836,633	-	9,461,575	2,365,394	17,740,452
Electrical Installation	1,851,131	-	742,928	185,732	1,293,935
Office Equipments	(7,787,386)	-	-	-	(7,787,386)
Machineries	104,812,346	-	13,990,525	3,497,631	94,319,452
Furniture & Fixtures	(6,531,810)	-	-	-	(6,531,810)
Total	**298,663,002**	**-**	**25,267,512**	**6,316,878**	**279,712,368**

Fixed assets were revalued by a firm of professional valuer in 2009 and the resulting increase of value has been shown as revaluation reserve . Depreciation charged on revaluation surplus against Building, Vahicles, Electrical Installation and Machineries for TK. 25,267,512 has been adjusted between revaluation reserve and retained earnings.

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
15.02	Tax Holiday Reserve is being carried forward from 2010.		5,503,099	5,503,099
15.03	Revaluation Reserve Adjustment: Tk. 25,267,512			

Range of Holdings	Revaluation Surplus	Useful Life (Years)	Depreciation on Revaluation Surplus
Land & Land Development	168,084,972	-	-
Building	21,449,683	20	1,072,484
Vehicles	47,307,873	5	9,461,575
Electrical Installation	7,429,282	10	742,928
Office Equipments	(7,787,386)	10	-
Machineries	209,857,872	15	13,990,525
Furniture & Fixture	(6,531,810)	10	-
Total	**439,810,486**	**-**	**25,267,512**

16.00	**RETAINED EARNINGS: TK. 406,443,764**			
	Opening Balance		376,890,123	369,704,848
	Add: Net Profit during the year		126,103,008	103,734,641
	Add: Revaluation Reserve adjustment		25,267,512	25,267,512
			528,260,642	**498,707,000**
	Less: Dividend For the year		115,500,000	115,500,000
	Less: Deferred Tax Adjustment		6,316,878	6,316,878
	Closing Balance		**406,443,764**	**376,890,123**
17.00	**LONG TERM LOAN: TK. 575,000,582**			
	Janata Bank Ltd.	**Note-17.01**	-	55,438,347
	Janata Bank Ltd. (Take Over Loan)	**Note-17.02**	-	82,187,350
	Agrani Bank Ltd.	**Note-17.03**	-	31,388,797
	Sonali Bank Ltd.	**Note-17.04**	-	93,058,482
	Rupali Bank Ltd.	**Note-17.05**	515,251,218	687,588,104
	Prime Finance & Investment Ltd.	**Note-17.06**	5,728,719	14,233,470
	Bangladesh Finance and Investment Company Ltd.	**Note-17.07**	27,446,899	12,755,180
	BRAC Bank Ltd.	**Note-17.08**	26,573,746	-
	Closing Balance		**575,000,582**	**976,649,730**
17.01	**Janata Bank Limited: Tk. 0**			
	Opening balance with current portion		57,404,198	
	Add: Received during the year		-	
	Add: Interest during the year		5,910,737	

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Less: Paid during the year		19,500,000	
	Less: Transfer to current portion of long term loan		43,814,935	
	Total		-	
	Details are as under:			
	Limit Amount	: Tk. 177,500,000		
	Purpose	: Factory Construction & Machineries		
	Security	: Land & Buildings		
	Interest Rate	: 11% per annum		
	Mode of Payment	: From own sources		
	Type of Facility	: Project loan		
	Validity	: Up to 2018		
17.02	**Janata Bank Ltd. (Take Over Loan): Tk. 0**			
	Opening balance with current portion		106,033,143	
	Add: Received during the year		-	
	Add: Interest during the year		7,032,129	
	Less: Paid during the year		116,876,085	
	Less: Transfer to current portion of long term loan		(3,810,813)	
	Total		-	
	Details are as under:			
	Limit Amount	: Tk. 368,621,000		
	Purpose	: Factory Construction & Machineries		
	Security	: Land & Buildings		
	Interest Rate	: 14% per annum		
	Mode of Payment	: From own sources		
	Type of Facility	: Project Loan		
	Validity	: Up to 30th June 2018		
17.03	**Agrani Bank Ltd: Tk. 0**			
	Opening balance		31,388,797	
	Add: Received during the year		-	
	Add: Interest & bank charge during the year		2,642,836	
	Less: Paid during the year		19,500,000	
	Less: Transfer to current portion of long term loan		14,531,633	
	Total		-	
	Details are as under:			
	Limit Amount	: Tk. 197,500,000		
	Purpose	: Factory Construction & Machineries		
	Security	: Land & Buildings		

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Interest Rate	: 13% per annum		
	Mode of Payment	: From own sources		
	Type of Facility	: Project Loan		
	Validity	: Up to 2018		
17.04	**Sonali Bank Ltd: Tk. 0**			
	Opening balance		93,058,482	
	Add: Received during the year		-	
	Add: Interest during the year		9,313,402	
	Less: Paid during the year		44,200,000	
	Less: Transfer to current portion of long term loan		58,171,884	
	Total		**-**	
	Details are as under:			
	Limit Amount	: Tk. 220,000,000		
	Purpose	: Factory Construction & Machineries		
	Security	: Land & Buildings		
	Interest Rate	: 12.5% per annum		
	Mode of Payment	: From own sources		
	Type of Facility	: Project Loan		
	Validity	: Up to 2018		
17.05	**Rupali Bank Ltd: Tk. 515,251,218**			
	Opening balance		687,588,104	
	Add: Received during the year		41,881,062	
	Add: Interest during the year		75,460,146	
	Less: Paid during the year		117,927,688	
	Less: Transfer to current portion of long term loan		171,750,406	
	Total		**515,251,218**	
	Details are as under:			
	Limit Amount	: Tk. 700,000,000		
	Purpose	: Land & Land Development		
	Security	: Land & Buildings		
	Interest Rate	: 14.5% per annum		
	Mode of Payment	: From own sources		
	Validity	: UP to 2022		
17.06	**Prime Finance & Investment Ltd: Tk. 5,728,719**			
	Opening balance		14,233,470	

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Add: Received during the year		-	
	Add: Interest during the year		3,514,728	
	Less: Paid during the year		6,290,760	
	Less: Transfer to current portion of long term loan		5,728,719	
	Total		**5,728,719**	
	Details are as under:			
	Limit Amount	: Tk. 20,000,000		
	Purpose	: Procurement of fixed assets		
	Security	: Vehicles		
	Interest Rate	: 11.75% per annum		
	Mode of Payment	: Through post dated cheque		
	Type of Facility	: Term finance		
	Validity	:Up to 2019		
17.07	**Bangladesh Finance and Investment Company Ltd: Tk. 27,446,899**			
	Opening balance		12,755,180	
	Add: Received during the year		31,131,000	
	Add: Interest during the year		4,684,267	
	Less: Paid during the year		11,974,582	
	Less: Transfer to current portion of long term loan		9,148,966	
	Total		**27,446,899**	
	Details are as under:			
	Limit Amount	: Tk. 45,000,000		
	Purpose	: Procurement of vehicles		
	Security	: Vehicles		
	Interest Rate	: 10.90% per annum		
	Mode of Payment	: From own sources		
	Type of Facility	: Lease finance		
	Validity	: Up to 2022		
17.08	**BRAC Bank Ltd: Tk. 26,573,746**			
	Opening balance		-	
	Add: Received during the year		36,760,000	
	Add: Interest during the year		906,119	
	Less: Paid during the year		2,234,458	
	Less: Transfer to current portion of long term loan		8,857,915	
	Total		**26,573,746**	

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Details are as under:			
	Limit Amount	: Tk. 40,000,000		
	Purpose	: To procure total 22 nos. of vehicles		
	Security	: Vehicles		
	Interest Rate	: 9.90% per annum		
	Mode of Payment	: From own sources		
	Type of Facility	: Lease Finance		
	Validity	: Up to 2022		
18.00	**CURRENT PORTION OF LONG TERM LOAN: TK. 308,193,645**			
	Janata Bank Ltd.		43,814,935	1,965,851
	Janata Bank Ltd. (Take Over Loan)		(3,810,813)	23,845,793
	Agrani Bank Ltd.		14,531,633	-
	Sonali Bank Ltd.		58,171,884	-
	Rupali Bank Ltd.		171,750,406	-
	Prime Finance & Investment Ltd.		5,728,719	-
	Bangladesh Finance and Investment Company Ltd.		9,148,966	-
	BRAC Bank Ltd.		8,857,915	-
	Closing Balance		**308,193,645**	**25,811,644**
19.00	**SHORT TERM LOAN: TK. 903,370,275**			
	PAD - Rupali Bank Ltd., Dhaka.	**Note-19.01**	-	6,946,140
	LC/TR - First Security Bank Ltd., Gulshan Branch, Dhaka	**Note-19.02**	6,604,515	24,995,796
	LC - Janata Bank Ltd., Janata Bhaban Branch, Motijheel, Dhaka	**Note-19.03**	-	3,115,822
	CC (Hypo)- Janata Bank Ltd., Corporate Bhaban Branch	**Note-19.04**	896,765,760	884,347,297
	Closing Balance		**903,370,275**	**919,405,055**
	Short term loan has been taken to meet up the working capital requirement and is secured by Inventories.			
19.01	**PAD - Rupali Bank Ltd., Dhaka: Tk. Nil**			
	Opening balance		6,946,140	
	Add: Received during the year		-	
	Add: Interest during the year		-	
	Less: Paid during the year		6,946,140	
	Total		**-**	
19.02	**LC/TR - First Security Bank Ltd., Gulshan Branch, Dhaka: Tk. 6,604,515**			
	Opening balance		24,995,796	
	Add: Received & interest during the year		65,415,500	
	Less: Paid during the year		83,806,781	
	Total		**6,604,515**	

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017

Details are as under:

Limit Amount	: Tk. 100,000,000
Purpose	: Import of Materials Packing materials, Spares and others items
Security	: Land & Buildings
Interest Rate	: 16% per annum
Mode of Payment	: From own sources

19.03 LC - Janata Bank Ltd., Janata Bhaban Branch, Motijheel, Dhaka: Tk. Nil

Opening balance	3,115,822
Add: Received during the year	1,180,378
Add: Interest during the year	-
Less: Paid during the year	4,296,200
Total	-

19.04 CC (Hypo)- Janata Bank Ltd., Corporate Bhaban Branch: Tk. 896,765,760

Opening balance	884,347,297
Add: Received during the year	249,867,088
Add: Interest during the year	91,669,877
Less: Paid during the year	329,118,502
Total	**896,765,760**

Details are as under:

Limit Amount	: Tk. 1,400,000,000
Purpose	: Meeting the requirement of working capital of the company
Security	: Inventory & Land
Interest Rate	: 12% per annum
Mode of Payment	: From own sources
Type of Facility	: CC Hypo

20.00 SHARE APPLICATION MONEY REFUNDABLE: TK. 4,323,613

Opening balance	4,323,613	4,333,613
Payment made during the year	-	10,000
Closing Balance	**4,323,613**	**4,323,613**

Share application money refundable amount as on 30.06.2018 was Tk. 4,323,613. The company has not paid or refund any amount during the year under audit and the balance amount remain unpaid although the company has received the amount during July 21, 2010.

21.00 ACCOUNTS PAYABLE: TK. 51,206,139

Payable to Suppliers	**Note-21.01**	30,054,621	66,298,520
Depot Expenses Payable	**Note-21.02**	2,935,521	1,681,980
Others Payable	**Note-21.03**	18,215,997	7,509,311
		51,206,139	**75,489,811**

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
21.01	**Payable to Suppliers: Tk. 30,054,621**			
	Against Raw Materials		1,991,431	426,770
	Against Laboratory Chemicals		1,923,860	2,180,935
	Against Computer & Accessories		1,385,962	767,865
	Against Plastic Items		1,811,584	1,959,477
	Against Machinery & Equipment		8,907,529	6,582,035
	Against Printing & Packaging Materials		8,023,546	7,260,992
	Against PVC & Foil suppliers		1,617,870	659,446
	Against Clearing & Forwarding		8,903,467	(4,670,850)
	Against Maintenance & Service		(4,227,778)	(1,168,474)
	Against Vehicles suppliers		(27,129,602)	(17,093,672)
	Against Construction Materials Suppliers		27,998,348	65,776,278
	Against Advertising		(687,885)	(646,809)
	Against Promotional Items		(11,624,796)	(4,403,605)
	Against Travel Agencies		(508,784)	(117,623)
	Against Transport & Courier		(355,461)	861,854
	Against Glass Item - Suppliers		(1,348,889)	(2,374,201)
	Against Furniture & Fixture		(368,384)	(589,145)
	Against Insurance Premium		13,742,520	11,451,640
	Against Misc. Suppliers		183,623	(380,853)
	Against Spare Parts		(183,540)	(183,540)
	Closing Balance		**30,054,621**	**66,298,520**
21.02	**Depot Expenses Payable: Tk. 2,935,521**			
	Rangpur Depot		847,086	806,049
	Bogura Depot		301,025	72,591
	Rajshahi Depot		(234,575)	(177,309)
	Khulna Depot		(78,757)	(52,666)
	Barisal Depot		(281,176)	(146,816)
	Faridpur Depot		(79,810)	(49,287)
	Mymensingh Depot		617,074	41,011
	Narayangonj Depot		5,762	15,745
	Comilla Depot		190,702	(167,482)
	Sylhet Depot		741,142	820,702
	Maizdhee Depot		(116,002)	(121,013)
	Chittagong Depot		241,600	161,763

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Central Distribution Centre		325,279	255,636
	Cox's Bazar		86,761	182,199
	Dhaka North Depot		(326,421)	(313,638)
	Dhaka South Depot		(52,962)	40,144
	Privilege Point		220,894	175,192
	B. Baria Depot		316,804	86,436
	Feni Depot		123,956	99,806
	Jessore Depot		(50,584)	(29,188)
	Dinajpur Depot		120,872	(17,895)
	Tangail Depot		16,851	-
	Closing Balance		**2,935,521**	**1,681,980**
21.03	**Others Payable: Tk. 18,215,997**			
	Received against Motor Cycle		9,753,810	5,145,185
	Earn leave payable		560,978	2,364,126
	Against Motor Car		7,901,209	-
	Closing Balance		**18,215,997**	**7,509,311**
	Accounts payable for supply of raw materials, packing materials & other promotional items are the regular suppliers of the Company and the amount are due on account.			
22.00	**ACCRUED EXPENSES: TK. 50,069,081**			
	Salary & Allowances		48,340,779	68,606,087
	Gas Bills		1,316,302	2,262,707
	Audit Fees		237,000	162,000
	Credit Rating Fees		150,000	150,000
	Compliance Audit Fees		25,000	-
	Closing Balance		**50,069,081**	**71,180,794**
23.00	**VAT PAYABLE: TK. 13,243,674**			
	Trade Creditors		10,015,059	5,441,687
	House rent		3,159,948	875,952
	Audit Fees		9,500	27,000
	Credit Rating Fees		25,000	25,000
	Compliance Audit Fees		4,167	-
	Advertisement & Publicity		-	68,736
	Closing Balance		**13,243,674**	**6,438,375**

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
24.00	**LIABILITY FOR EWF & WPPF: TK. 22,779,093**			
	Employees Welfare Fund (EWF)	Note-24.01	2,686,246	2,581,344
	Workers Profit Participation Fund (WPPF)	Note-24.02	20,092,848	16,771,060
	Closing Balance		**22,779,093**	**19,352,404**
24.01	**Employees Welfare Fund (EWF): Tk. 2,686,246**			
	Opening Balance		2,581,344	2,337,862
	Add: Contribution during the year		762,972	589,956
	Total Contribution		**3,344,316**	**2,927,818**
	Less: Paid to the employees		658,070	346,474
	Closing Balance		**2,686,246**	**2,581,344**
24.02	**Workers Profit Participation Fund: Tk. 20,092,848**			
	Opening Balance		16,771,060	13,276,261
	Add: Contribution during the year		6,301,788	5,794,799
	Total Contribution		**23,072,848**	**19,071,060**
	Less: Paid to the employees		2,980,000	2,300,000
	Closing Balance		**20,092,848**	**16,771,060**
25.00	**PROVISION FOR EMPLOYEES' PROVIDENT FUND:TK. 6,352,182**			
	Opening Balance		10,966,918	8,130,962
	Addition made during the year		31,650,430	23,855,598
	Total		**42,617,348**	**31,986,560**
	Less: Paid to the Fund during the year		36,265,166	21,019,642
	Closing Balance		**6,352,182**	**10,966,918**
26.00	**PROVISION FOR GRATUITY: TK. 28,336,371**			
	Opening Balance		16,053,742	17,761,641
	Addition made during the year		16,306,881	-
	Total		**32,360,623**	**17,761,641**
	Less: Gratuity paid during the year		4,024,252	1,707,899
	Closing Balance		**28,336,371**	**16,053,742**
27.00	**TAX PAYABLE: TK. -89,671,334**			
	Corporate Tax Liability	**Note-27.01**	(93,603,174)	(41,819,183)
	Other Tax Liability	**Note-27.02**	3,931,840	13,783,464
			(89,671,334)	**(28,035,719)**
27.01	**CORPORATE TAX LIABILITY : TK.-93,603,174**			
	Opening Balance		(41,819,183)	(34,521,105)

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Tax on current year's profit		31,508,938	28,973,996
	Total tax liabilities		**(10,310,245)**	**(5,547,109)**
	Less: TDS/Advance paid tax			
	For income year 2017-18		83,292,929	36,272,074
	Total Corporate Tax Liability		**(93,603,174)**	**(41,819,183)**
27.02	**OTHER TAX LIABILITY: TK. 3,931,840**			
	TDS from Salary & Allowances		473,450	1,001,747
	TDS from Trade Creditors		771,526	10,661,191
	TDS from Office Rent		983,509	119,686
	TDS from Managing Director's Remuneration		1,616,875	1,896,200
	TDS from Gas Bills		40,702	69,973
	TDS from Audit Fee		26,333	18,000
	TDS from Compliance Audit Fee		2,778	-
	TDS Credit Rating Fee		16,667	16,667
	Closing Balance		**3,931,840**	**13,783,464**
28.00	**DIVIDENT PAYABLE: TK. 34,463,510**			
	Opening Balance		17,042,997	100,018,892
	Add: Addition during the Year		100,560,591	-
			117,603,588	**100,018,892**
	Less: Dividend paid during the year		83,140,078	82,975,895
	Closing Balance		**34,463,510**	**17,042,997**
29.00	**TURNOVER: TK. 3,760,786,106**			
	Local Sales		3,571,203,459	2,845,007,213
	Export Sales		189,582,647	103,449,296
	Net Turnover		**3,760,786,106**	**2,948,456,509**
	Details of Turnover are as under:			
	Product Group		**Box/Pack**	**Net Sales**
	Injection		2,385,575	1,006,979,483
	Tablet		7,105,787	1,775,676,951
	Pre-Filled Syringe		94,906	106,978,595
	Infusion		560,604	105,416,521
	Capsule		1,589,763	538,622,683
	Syrup		2,087,219	136,247,370
	PFS		754,742	90,864,503
			14,578,596	**3,760,786,106**

BEACON PHARMACEUTICALS LTD.

Notes to the Financial Statements

For the year ended 30 June, 2018

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
30.00	**COST OF GOODS SOLD: TK. 1,927,331,673**			
	Materials Consumed	**Note-30.01**	1,131,911,400	830,673,247
	Factory Overhead	**Note-30.02**	733,713,416	554,580,148
	Total Manufacturing Cost		**1,865,624,816**	**1,385,253,395**
	Add: Opening Work-in-Process		85,102,385	86,965,316
	Total Work-in-Process		**1,950,727,201**	**1,472,218,711**
	Less: Closing Work-in-Process		135,588,281	85,102,385
	Cost of Production		**1,815,138,920**	**1,387,116,326**
	Add: Opening Finished Goods		338,227,070	435,734,440
	Finished Goods available for Sale		**2,153,365,990**	**1,822,850,766**
	Less: Closing Finished Goods		226,034,317	338,227,070
	Cost of Goods Sold		**1,927,331,673**	**1,484,623,696**
30.01	**Materials Consumed: Tk. 1,131,911,400**			
	Opening Inventory (Raw & Packing Material)		659,545,918	652,826,801
	Add: Purchase		1,107,676,021	837,392,364
	Materials available for use		1,767,221,939	1,490,219,165
	Less: Closing Raw & Packing Material		635,310,539	659,545,918
	Total		**1,131,911,400**	**830,673,247**
30.02	**Factory Overhead: Tk. 733,713,416**			
	Salaries & Allowances		149,744,140	111,208,330
	Co's Contribution to P.F		2,774,311	2,080,357
	Gratuity		2,575,744	-
	Local Travel & Conveyance		518,263	402,519
	Foreign Travel		1,918,428	979,188
	Entertainment		1,325,574	661,181
	Employee Fooding		27,281,076	16,238,423
	Employee Pick & Drop		5,850,674	4,145,951
	Telephone, Fax, Internet		2,510,297	1,878,813
	Utilities		25,633,987	19,133,657
	Fees & Renewal		609,801	334,168
	Books, News Paper & Periodicals		12,268	8,726
	Printing & Stationery		10,768,848	7,450,832
	Legal & Consultancy Fees		1,839,489	2,462,133
	Insurance Premium		591,087	400,330
	Handling & Carrying Expense		259,900	241,190
	Research & Development Expense		14,993,744	7,488,003
	Repairs & Maintenance		15,820,810	4,075,842

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
	Training Expense		1,611,324	468,425
	Advertisement & Publicity		89,762	24,405
	Misc. Expense		129,123	37,591
	Tool Manufacturing Expense		16,049,611	15,383,369
	Depreciation		450,805,155	359,476,715
	Total		**733,713,416**	**554,580,148**
31.00	**ADMINISTRATIVE EXPENSES: TK. 239,590,025**			
	Salaries & Allowances		106,218,037	68,737,689
	Co's Contribution to P.F		1,656,115	1,111,245
	Gratuity		3,897,451	-
	Local Travel & Conveyance		1,938,982	1,692,729
	Foreign Traveling Expenses		2,761,533	2,032,515
	Entertainment		4,668,745	2,923,090
	Employee Fooding		26,266,500	33,708,270
	Office Rent		19,227,468	1,165,000
	Employee Pick & Drop		16,757,242	6,332,954
	Utilities		5,917,796	882,520
	Telephone, Fax, Courier		4,795,305	2,858,106
	Fees & Renewals		4,819,047	1,651,812
	Books, News Paper & Periodicals		58,457	42,258
	Printing & Stationery		4,209,848	2,924,020
	Audit Fee		382,056	207,000
	Legal & Consultancy Fees		2,170,394	2,993,529
	Insurance Premium		3,109,137	2,313,137
	Bank Charge & Other Expense		1,007,025	970,881
	Renewal & Documentation Expense		-	1,065,000
	Handling & Carrying Expense		1,115,634	10,000
	Repairs & Maintenance		2,244,230	638,899
	Advertisement & Publicity		2,502,034	1,472,550
	Training Expense		1,484,122	1,240,341
	Misc. Expense		2,567,256	1,508,724
	Depreciation		19,815,611	15,801,174
	Total		**239,590,025**	**154,283,443**

Salaries and allowances increased due to the increase of the numbers of employees and increment as well.

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
32.00	**MARKETING, SELLING & DISTRIBUTION EXPENSES: TK. 1,324,256,067**			
	Salaries & Allowances		517,022,714	420,734,182
	Co's Contribution to P.F		11,367,574	8,728,561
	Gratuity		9,833,686	-
	Local Travel & Conveyance		25,112,955	10,515,372
	Foreign Travel		15,448,497	10,457,303
	Entertainment		4,758,265	4,023,013
	Employee Fooding		6,641,470	6,836,205
	Depot Rent		11,396,575	10,083,855
	Employees Pick & Drop		3,500,272	2,950,451
	Utilities		1,872,110	1,319,151
	Telephone, Fax, Internet		9,809,015	6,233,466
	Fees & Renewal		1,883,750	743,926
	Books, News Paper & Periodicals		25,704	4,670
	Printing & Stationery		14,432,882	14,835,069
	Legal & Consultancy Fees		310,776	180,208
	Insurance Premium		4,532,846	2,089,571
	Bank Charges		2,486,655	2,108,524
	Handling & Carrying		1,087,692	2,760,437
	Repairs & Maintenance		1,861,223	1,537,360
	Research & Product Development		3,107,270	3,008,499
	Field Force Expenses (TA/DA)		91,310,534	84,609,209
	Sales Incentive		7,379,190	8,537,707
	Training Expense		4,608,659	3,134,171
	Conference, fair and product launching		58,799,283	79,731,867
	Promotional Expense		403,565,711	251,536,305
	Advertisement & Publicity		3,601,389	1,918,374
	Distribution & Collection Expenses		81,706,478	73,020,165
	Misc. Expense		2,023,378	10,885,242
	Depreciation		24,769,514	19,751,468
	Total		**1,324,256,067**	**1,042,274,331**
33.00	**FINANCIAL EXPENSES: TK. 138,082,326**			
	Interest on Consortium Loan	**Note-33.01**	44,766,236	44,328,437
	Interest on Short Term Loan	**Note-33.02**	91,644,877	102,800,716
	Bank Charges Other	**Note-33.03**	1,671,213	245,865
	Total		**138,082,326**	**147,375,018**

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017
33.01	**Interest on Consortium Loan : TK. 44,766,236**			
	Janata Bank Ltd.		5,910,737	7,751,495
	Janata Bank Ltd. (Takeover)		(643,956)	18,443,075
	Agrani Bank Ltd.		2,642,836	4,267,986
	Sonali Bank Ltd.		9,313,402	13,865,881
	BD Finance Ltd.		4,684,267	-
	BRAC Bank Ltd.		828,162	-
	Prime Finance Ltd.		3,514,728	-
	Rupali Bank Ltd.		18,516,060	-
	Total		**44,766,236**	**44,328,437**
33.02	**Interest on Short Term Loan:Tk.9,16,44,877**			
	CC(Hypo) - Janata Bank Ltd., Corporate Bhaban, Motijheel		91,644,877	102,800,716
	Total		**91,644,877**	**102,800,716**
33.03	**Bank Charges Other: Tk.16,71,213**			
	Bank Charge & Others		1,671,213	245,865
	Total		**1,671,213**	**245,865**
34.00	**INCOME FROM OTHER SOURCES: TK. 811,526**			
	Interest Received from Bank		688,477	346,544
	Interest on FDR		122,507	-
	Received from Scrap Sales & others		-	351,128
	Dividend Income		542	1,093,091
	Total		**811,526**	**1,790,763**
35.00	**CONTRIBUTION TO WORKERS PROFIT PARTICIPATION FUND:Tk. 6,301,788**			
	WPPF Fund contribution during the year		6,301,788	5,794,799
	Total		**6,301,788**	**5,794,799**

35.01 As per provision of Section 234 of the Bangladesh Labor Law 2006 as amended, 5% of net profit before tax is contributed to the above fund in the following proportions:

Particulars	Proportion	30 June 2018
Contribution to Participatory Fund	80%	5,041,430
Contribution to Welfare Fund	10%	630,179
Contribution to WWFF	10%	630,179
Total Taka		**6,301,788**

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017

36.00 UNREALIZED (LOSS)/GAIN ON QUOTED SHARES : TK.-1,159,389

Unrealized Gain Realized	-	-
Unrealized (loss)/gain during the year	(1,159,389)	975,875
Total Taka	**(1,159,389)**	**975,875**

37.00 EARNINGS PER SHARE (EPS):

Basic Earnings Per Share

Breakup of the above amount is given below:

Particulars	30 June 2018	30 June 2017
Net Profit After Tax	126,103,008	103,734,641
Ordinary Shares Outstanding During the year	231,000,000	231,000,000
Earnings Per Share:	**0.55**	**0.45**

Calculation of weighted average number of share was not required since no shares were issued during the year.

38.00 PAYMENT TO DIRECTORS: TK. 25,200,000

The aggregate amount paid (except Directors fees for attending board meetings)during the year to the director of the company is given below as per requirement of Securities and Exchange Rules 1987.

Particulars	30 June 2018	30 June 2017
Basic Remuneration	7,200,000	5,700,000
House Rent	3,600,000	300,000
Medical allowance	1,800,000	-
Conveyance	1,800,000	-
Other allowances	9,600,000	-
Bonus	1,200,000	-
Total	**25,200,000**	**6,000,000**

39.00 CLAIMS AGAINST THE COMPANY NOT ACKNOWLEDGED AS DEBT:

None as on 30-06-2018.

40.00 CREDIT FACILITIES NOT AVAILED:

There is no credit facility available to the Company that was not availed as on 30-06-2018 under any contract, other than those mentioned in the financial statements arising in the ordinary course of business.

41.00 DISCLOSURES AS OER REQUIREMENT OF SCHEDULE XI, PART OF THE COMPANIES ACT,1994:

Total number of Employees Drawing Remuneration is as follows : 2,518

Breakup of the above amount is given below:

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017

Salary Range	No.of employees	No.of employees
No.of Employees Having Salary Between Tk. 4,000 to Tk. 5,000	-	-
No.of Employees Having Salary Between Tk. 5,000 to Tk. 10,000	554	787
No.of Employees Having Salary Between Tk. 10,000 to Tk. 15,000	589	828
No.of Employees Having Salary Between Tk. 15,000 to Tk. 25,000	814	408
No.of Employees Having Salary Between Tk. 25,000 to Tk. 50,000	441	210
No.of Employees Having Salary Between Tk. 50,000 and above	120	125
Total	**2,518**	**2,358**

42.00 Capacity Utilization: Tk. 2,325

Production capacity and current utilization as required by the companies Act 1994, Schedule-XI, Para-7. Actual production and utilization for major products groups are as follows.

Major product/Unit	Capacity (In Millions)	30 June 2018		30 June 2017	
		Actual Production (In Millions)	Utilization (%)	Actual Production (In Millions)	Utilization (%)
Tablets	2,100	1,421	68%	1,159	55%
Capsules (Filled with Pellets)	80	289	76%	205	54%
Capsules (Filled with Powder)	850	592	70%	449	53%
Powder for suspension(Bottles)	15	11	73%	8	56%
Injection (Ampoules)	5	3	63%	3	54%
Injection (Lyophilized)	5	4	76%	3	54%
Large Volume Parenteral	4	3	70%	2	54%
Pre-filled Syringe	4	3	78%	2	52%
Total	**3,363**	**2,325**		**1,831**	

43.00 RELATED PARTY DISCLOSURES: TK. 339,209,477

During the year the company carried out a number of transaction with related parties in the normal course of business on an arm's length basis. Name of those related parties, nature of those transaction and their total value has been shown in the below table in accordance with BAS-24 " Related Party disclosures.

Notes Sl. No.	Particulars	Note Ref.	Amount in Taka	
			30 June 2018	30 June 2017

Name of the parties	Relationship	nature of transaction	Opening balance	Addition	Adjustment	Closing Balance
Beacon Glass Industries Ltd.	Shareholders	Investment In Shares	103,005,125	-	-	103,005,125
Mujibunnesa Medical College & Hospital Ltd.	Shareholders	Investment In Shares	94,809,180	-	-	94,809,180
Beacon Cephalosporin Ltd.	Shareholders	Investment In Shares	177,640,868	92,200,000	197,640,868	72,200,000
Beacon Power Systems Ltd.	Shareholders	Investment In Shares	69,195,172	-	-	69,195,172
Total			**444,650,345**	**92,200,000**	**197,640,868**	**339,209,477**

44.00 EVENT AFTER THE REPORTING PERIOD:

The Board of Directors in its' meeting held on 21st October, 2018 has recommended 6% cash dividend for the year ended June 30, 2018 subject to approval of the shareholders at the ensuing Annual General Meeting (AGM).

45.00 CONTINGENT LIABILITIES:

There may arise tax liability on final assessment of tax remain pending with taxation authority. Without the above, there is no known contingent liabilities.

BEACON PHARMACEUTICALS LTD.

FIXED ASSETS SCHEDULE

As at 30 June, 2018

Annexure-A

Particulars	COST					DEPRECIATION				Written Down Value as on 30.06.18
	Balance as on 01.07.2017	Addition During the year	Adjustment During the year	Balance as on 30.06.2018	Rate (%)	Depreciation as on 01.07.2017	Charged During the year	Adjustment During the year	Depreciation as on 30.06.2018	
Land & Land Development	503,090,574	-	-	503,090,574	0%	-	-	-	-	503,090,574
Factory Building	613,320,398	304,633,786	-	917,954,184	5%	232,261,732	32,191,905	-	264,453,637	713,957,131
Corporate Head Office Building	30,517,707	29,938,877	-	60,456,584						
Vehicles	86,924,762	80,566,078	-	167,490,840	20%	19,361,397	27,339,849	-	46,701,246	120,789,594
Electrical Installations	73,008,452	15,651,293	-	88,659,745	10%	36,609,657	8,227,742	-	44,837,399	43,822,346
Office Equipment	73,464,529	33,974,059	-	107,438,588	10%	28,561,892	8,478,402	-	37,040,294	70,398,294
Production Machinery & Equipment	2,648,591,502	173,675,798	-	2,822,267,300	15%	1,776,340,151	403,848,793	-	2,180,188,944	642,078,356
Furniture & Fixture	151,675,495	3,989,185	-	155,664,680	10%	17,998,752	15,303,589	-	33,302,341	122,362,340
30-06-2018	**4,180,593,419**	**642,429,076**	-	**4,823,022,495**		**2,111,133,581**	**495,390,280**	-	**2,606,523,861**	**2,216,498,633**
30-06-2017	**3,401,685,777**	**778,907,642**	-	**4,180,593,419**		**1,716,104,224**	**395,029,357**	-	**2,111,133,581**	**2,069,459,838**

Allocation of Depreciation:	Proportion	Amount(Tk.)
Factory Overhead	91%	450,805,155
Administrative Overhead	4%	19,815,611
Selling, Marketing Expenses	5%	24,769,514
Total	**100%**	**495,390,280**

BEACON®
Pharmaceuticals Limited
Light for life

Corporate Office:

BEACON Business Centre
9/B/2 Toyenbee Circular Road (Box Culvert Road),
Motijheel C/A, Dhaka-1223, Bangladesh.
Tel : +880-2-57165371-76, Fax : +880-2-57165379
E-mail : beacon@beaconpharma.com.bd
Website : www.beaconpharma.com.bd

NOTICE OF THE 17th ANNUAL GENERAL MEETING

Notice is hereby given that the 17th Annual General Meeting of the Shareholders of Beacon Pharmaceuticals Limited will be held on Sunday, 09th December, 2018 at 11.00 a.m at its Registered Office at Kathali, Bhaluka, Mymensingh (Factory Premises) to transact the following business:

Agenda

1. To receive, consider and adopt the Directors' and Auditors' Report and the Audited Accounts of the Company for the year ended 30th June, 2018.
2. To declare dividend for the year ended 30th June, 2018.
3. To elect Directors.
4. To approve the re-appointment of Chairman.
5. To appoint External & Complience Auditors and fix their remuneration.
6. To approve the re-appointment of Independent Directors.
7. To transact any other business with the permission of the Chair.

By order of the Board

Giash Uddin Ahmed FCMA
Company Secretary
15th November, 2018

Corporate Office
Beacon Business Centre
9/B/2, Toyenbee Circular Road, Motijheel C/A
Dhaka-1223, Bangladesh.

1. Shareholders whose names appeared at the record date i.e. 15th November, 2018 in the share register of the Company or in the depository register on that date will be eligible to attend and vote in the Annual General Meeting.
2. Member entitled to attend at the Annual General Meeting may appoint a proxy to attend and vote on his / her behalf. The proxy form must be affixed with requisite revenue stamp and must be submitted to the Corporate office of the Company not later than 48 hours before the time fixed for the Annual General Meeting.
3. The concerned brokerage houses & merchant bankers are requested to provide us with a statement with the details (shareholders name, BO ID number, e-TIN number, gross dividend receivable, applicable tax rate, and net dividend receivable) of their margin loan holders who hold shares of the Company as on the Record Date, along with the name of the contact person in this connection. The brokerage houses & merchant bankers are also requested to provide us with their Bank Account Name, number, routing number etc. on or before 30th November, 2018.
4. The concerned trustee board of approved superannuation fund or pension fund or gratuity fund or recognize provided fund or workers profit participation fund are requested to provide us update tax rebate certificate on or before 30th November, 2018.

Admission in the meeting venue will be allowed on production of the attendance slip attached with the proxy form.

Annual General Meeting 2017

















BEACON IN ACTION BOTH

Locally & Globally



"Treatment & Rehabilitation of Addiction problems in Bangladesh-2017" Beacon point limited achieved first prize **Mr. Md. Ebadul Karim**, Honorable Chairman, Beacon Point Ltd, receives the first prize award from Mr. Asaduzzaman Khan, MP, honorable Minister for Home Affairs, Govt. People's republic of Bangladesh.



Beacon Pharmaceuticals Limited received **"Contribution Towards Humanity"** award from Association of Colon & Rectal Surgeons of India(ACRSI) for producing lifesaving cancer-drugs and make it available to the 114 countries.



Father's Day Celebration on 28th June, 2018 at Beacon Corporate Office.



CCM Meeting, ICQCC-2018 at Singapore



BEACON organized a Cycle Rally to celebrate **World Mental Health Day 2018**



Beacon Oncology Limited arranged **"Women's Marathon"** at Hatirjheel, Dhaka for rising awareness against breast cancer.



Beacon Annual Sales Conference 2017 at Cox's Bazar.



Beacon Pharmaceuticals Ltd. participated "Bangladesh Association of Pharmaceuticals Job Fair" at Hotel Lakeshore, Gulshan,Dhaka. The Slogan was, **"Don't just dream, rather live it with the pioneers"**.

NOTES

NOTES

NOTES

BEACON® Pharmaceuticals Limited
Light for life

Proxy Card

This Proxy card is for use at the Annual General Meeting of BEACON Pharmaceuticals Limited to be held on Sunday, December 09, 2018.

I/We.....

Having BO ID # ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

of.....

Being a member of the Company do hereby appoint Mr./Ms. .....

of ..... to be my/our proxy to attend and vote on my/our behalf at the 17th Annual General Meeting of the Company to be held on Sunday, December 09, 2018 at 11.00 a.m at the Registered Office of BEACON Pharmaceuticals Limited at Kathali, Bhaluka, Mymensingh (Factory Premises) and at any adjournment thereof.

Signature of Proxy

Revenue Stamp of Tk. 20/-

Signature of the Shareholder

Notes: This form of proxy, duly completed, must be deposited at least 48 hours before the meeting at the Company's Share department at Corporate Office, Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223, Bangladesh. Proxy will be invalid if not signed and stamped as shown above. Signature of the shareholder should agree with the specimen signature registered with the Company.

BEACON® Pharmaceuticals Limited
Light for life

Attendance Slip

I do hereby record my attendance of the 17th Annual General Meeting of the Company to be held on Sunday, 09 December 2018 at 11.00 a.m at the Registered Office of BEACON Pharmaceuticals Limited at Kathali, Bhaluka, Mymensingh (Factory Premises).

Name of the Shareholder : .....

Folio No : ..... Nos. of shares held : .....

BO ID ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Signature of the Shareholder/Proxy

Dated : .....

Notes: Shareholders attending the meeting in person or by proxy are requested to deposit the attendance slip duly filled in at the entrance of the meeting hall. Seats in the auditorium are reserved only for the shareholders/proxies.

BEACON®
Pharmaceuticals Limited
Light for life

Corporate Office:

BEACON Business Centre
9/B/2, Toyenbee Circular Road
Motijheel C/A, Dhaka - 1223, Bangladesh.
E-mail : beacon@beaconpharma.com.bd
Website : www.beaconpharma.com.bd